var title_f4_5_4176="Prurigo nodularis arms";
var content_f4_5_4176=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86964&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86964&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Prurigo nodularis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 246px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_5_4176=[""].join("\n");
var outline_f4_5_4176=null;
var title_f4_5_4177="Edoxudine: International drug information";
var content_f4_5_4177=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"13\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Edoxudine: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4303342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Edurid (CH, DE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1978670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiviral Agent, Topical",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1978673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of herpes simplex",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1978669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Topical: Apply 6 times/day",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1978672\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Cream: 3%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Gel: 1.2% (10 g)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10375 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-83.177.194.223-190351C039-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_5_4177=[""].join("\n");
var outline_f4_5_4177=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4303342\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978670\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978673\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978669\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821105\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978672\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10375\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10375|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_5_4178="Patient information: Bipolar disorder (The Basics)";
var content_f4_5_4178=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"10\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15348\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/44/40640\">",
"         Mood disorders caused by problems in the brain",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?11/57/12179\">",
"         Patient information: Depression (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?38/55/39796\">",
"         Patient information: Bipolar disorder (manic depression) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Bipolar disorder (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/bipolar-disorder-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H46666873\">",
"      <span class=\"h1\">",
"       What is bipolar disorder?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Bipolar disorder (sometimes called &ldquo;manic depression&rdquo;) is a brain disorder that causes extreme changes in mood and behavior (",
"      <a class=\"graphic graphic_figure graphicRef60356 \" href=\"UTD.htm?39/44/40640\">",
"       figure 1",
"      </a>",
"      ). Bipolar disorder can run in families.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H46666880\">",
"      <span class=\"h1\">",
"       What are the symptoms of bipolar disorder?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People with bipolar disorder can feel much happier or much sadder than normal. If you have bipolar disorder, you may feel very happy for many days and then feel very sad.",
"     </p>",
"     <p>",
"      When your mood is very happy, you can also:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Get angry quickly",
"       </li>",
"       <li>",
"        Be more active than normal",
"       </li>",
"       <li>",
"        Feel like you have special powers",
"       </li>",
"       <li>",
"        Feel like you don&rsquo;t need sleep",
"       </li>",
"       <li>",
"        Make poor choices without thinking",
"       </li>",
"       <li>",
"        Start lots of things and not finish them",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Other times, your mood may be very sad for most of the day, every day. When your mood is very sad, you can also:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Lose or gain a lot of weight",
"       </li>",
"       <li>",
"        Have trouble falling asleep or sleep too much",
"       </li>",
"       <li>",
"        Feel very tired",
"       </li>",
"       <li>",
"        Not enjoy things",
"       </li>",
"       <li>",
"        Feel bad about yourself",
"       </li>",
"       <li>",
"        Think about death or hurting yourself",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People with bipolar disorder may have trouble at work or school. They may not get along well with their family and friends.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H46666887\">",
"      <span class=\"h1\">",
"       Is there a test for bipolar disorder?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. There is no test. But your doctor or nurse should be able to tell if you have it by talking with you and your family. He or she will ask about your mood and what you have been feeling and doing. Your doctor or nurse may also do an exam and order blood tests to look for other problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H46666894\">",
"      <span class=\"h1\">",
"       How is bipolar disorder treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Bipolar disorder is treated with medicine. Talk therapy can also help. Medicines sometimes take a while to start working. Plus, it sometimes takes a few tries to find the right medicine or combination of medicines.",
"     </p>",
"     <p>",
"      You and your doctor will work together to find the medicine that works best for you. All of the medicines for bipolar disorder affect the brain. They can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Keep your mood even and prevent big mood changes",
"       </li>",
"       <li>",
"        Calm your mind",
"       </li>",
"       <li>",
"        Make your sadness go away",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Medicines sometimes cause side effects.",
"     </p>",
"     <p>",
"      You may also need to stay in the hospital for a short time. When a bipolar disorder mood episode starts, you might be at risk of hurting yourself or others. You may hear voices that other people do not hear. You may believe things that are not true. But if you are at the hospital, the doctors can treat these symptoms and keep you safe.",
"     </p>",
"     <p>",
"      Some people whose bipolar disorder makes them feel very sad may need &ldquo;shock treatment&rdquo; to get better. Doctors call this treatment ECT. During ECT, doctors shock a person&rsquo;s brain in a safe way.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H46666901\">",
"      <span class=\"h1\">",
"       Is there anything I can do to prevent big mood changes in the future?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. After your symptoms have gone away, you will probably:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Keep taking medicine every day to help keep your mood and behavior even",
"       </li>",
"       <li>",
"        Go to talk therapy to help you get along better with family and friends",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H46666908\">",
"      <span class=\"h1\">",
"       What if I want to get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you want to get pregnant, you will need to talk with your doctor. Some medicines for bipolar disorder are OK to take if you are pregnant. Others are not. You might need to slowly reduce or change your medicine.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H46666915\">",
"      <span class=\"h1\">",
"       What will my life be like?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Many people with bipolar disorder are able to live normal lives, but they might:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Have times of feeling very happy or very sad again in the future",
"       </li>",
"       <li>",
"        Take drugs or drink alcohol. If this happens, talk to your doctor.",
"       </li>",
"       <li>",
"        Try to hurt themselves. If you ever feel like hurting yourself, call your doctor, go to the hospital, or dial 9-1-1.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H46666922\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/57/12179?source=see_link\">",
"       Patient information: Depression (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/55/39796?source=see_link\">",
"       Patient information: Bipolar disorder (manic depression) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?4/5/4178?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15348 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-B007036579-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_5_4178=[""].join("\n");
var outline_f4_5_4178=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H46666873\">",
"      What is bipolar disorder?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H46666880\">",
"      What are the symptoms of bipolar disorder?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H46666887\">",
"      Is there a test for bipolar disorder?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H46666894\">",
"      How is bipolar disorder treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H46666901\">",
"      Is there anything I can do to prevent big mood changes in the future?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H46666908\">",
"      What if I want to get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H46666915\">",
"      What will my life be like?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H46666922\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15348\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/44/40640\">",
"      Mood disorders caused by problems in the brain",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/55/39796?source=related_link\">",
"      Patient information: Bipolar disorder (manic depression) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/57/12179?source=related_link\">",
"      Patient information: Depression (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_5_4179="Crotamiton: Pediatric drug information";
var content_f4_5_4179=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Crotamiton: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?12/45/13011?source=see_link\">",
"    see \"Crotamiton: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?12/38/12900?source=see_link\">",
"    see \"Crotamiton: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F155020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Eurax&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F14959735\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Eurax Cream",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1046660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Scabicidal Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1046655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/45/13011?source=see_link\">",
"      see \"Crotamiton: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical: Infants, Children, and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Scabicide: Apply over entire body below the head; apply once daily for 2 days followed by a cleansing bath 48 hours after the last application; treatment may be repeated after 7-10 days if mites appear",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Pruritus: Massage into affected areas until medication is completely absorbed; may repeat as necessary",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F155009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Eurax&reg;: 10% (60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Eurax&reg;: 10% (60 mL, 480 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F154995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1046663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical: Wash thoroughly and scrub away loose scales, then towel dry; apply a thin layer and gently massage drug onto skin of the entire body from the neck to the toes (with special attention to skin folds, creases, and interdigital spaces); also apply cream or lotion under fingernails after trimming nails short; since scabies can affect the head, scalp, and neck in infants and young children, apply to scalp, neck, and body of this age group; do not apply to the face, eyes, mouth, mucous membranes, or urethral meatus; shake lotion well before use",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1046657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1046662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of scabies (",
"     <i>",
"      Sarcoptes scabiei",
"     </i>",
"     ) in infants and children; symptomatic treatment of pruritic skin",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F155058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Eurax&reg; may be confused with Efudex&reg;, Eulexin, Evoxac&reg;, Serax, Urex",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Eurax [U.S., Canada, and multiple international markets] may be confused with Urex brand name for furosemide [Australia, China,Turkey] and methenamine [U.S., Canada]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F155056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Contact dermatitis, pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Local irritation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic sensitivity reactions, warm sensation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1046666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to crotamiton or any component; patients who manifest a primary irritation response to topical medications",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1046654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid contact with face, eyes, mucous membranes, and urethral meatus; do not apply to acutely inflamed or raw skin",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F155004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F155006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F155015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted; use during pregnancy only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1046653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Mechanism for scabicidal activity is unknown",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1046665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Absorption: Amount of systemic absorption following topical use has not been determined",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1046659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/38/12900?source=see_link\">",
"      see \"Crotamiton: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For topical use only. Not for ophthalmic, oral, or intravaginal use. All contaminated clothing and bed linen should be washed to avoid reinfestation.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1046667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment may be repeated after 7-10 days if live mites are still present",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Eichenfield LF, Honig PJ, &ldquo;Blistering Disorders in Childhood,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1991, 38(4):959-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/5/4179/abstract-text/1651468/pubmed\" id=\"1651468\" target=\"_blank\">",
"        1651468",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hogan DJ, Schachner L, Tanglertsampan C, &ldquo;Diagnosis and Treatment of Childhood Scabies and Pediculosis,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1991, 38(4):941-57.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/5/4179/abstract-text/1870912 /pubmed\" id=\"1870912 \" target=\"_blank\">",
"        1870912",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13186 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.75.47.146-274201436B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_5_4179=[""].join("\n");
var outline_f4_5_4179=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155020\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14959735\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046660\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046655\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155009\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154995\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046663\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046657\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046662\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155058\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155056\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046666\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046654\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299103\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155004\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155006\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155015\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046653\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046665\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046659\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046667\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13186\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13186|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/45/13011?source=related_link\">",
"      Crotamiton: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/38/12900?source=related_link\">",
"      Crotamiton: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_5_4180="Acquired ungual fibrokeratoma";
var content_f4_5_4180=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85594&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85594&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Acquired ungual fibrokeratoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 521px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_5_4180=[""].join("\n");
var outline_f4_5_4180=null;
var title_f4_5_4181="Dermatomyositis scalp";
var content_f4_5_4181=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F64903&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F64903&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Scalp involvement in dermatomyositis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Scale and erythema are present on the scalp in this patient with dermatomyositis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_5_4181=[""].join("\n");
var outline_f4_5_4181=null;
var title_f4_5_4182="Acetaminophen, dextromethorphan, and phenylephrine: Drug information";
var content_f4_5_4182=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Acetaminophen, dextromethorphan, and phenylephrine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?29/54/30565?source=see_link\">",
"    see \"Acetaminophen, dextromethorphan, and phenylephrine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F5093662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Alka-Seltzer Plus&reg; Day Cold [OTC];",
"     </li>",
"     <li>",
"      Comtrex&reg; Maximum Strength, Non-Drowsy Cold &amp; Cough [OTC];",
"     </li>",
"     <li>",
"      Daytime Cold &amp; Flu Relief Multi-Symptom [OTC] [DSC];",
"     </li>",
"     <li>",
"      Mapap&reg; Multi-Symptom Cold [OTC];",
"     </li>",
"     <li>",
"      Theraflu Warming Relief&reg; Daytime Multi-Symptom Cold [OTC];",
"     </li>",
"     <li>",
"      Theraflu Warming Relief&reg; Daytime Severe Cold &amp; Cough [OTC];",
"     </li>",
"     <li>",
"      Theraflu&reg; Daytime Severe Cold &amp;  Cough [OTC];",
"     </li>",
"     <li>",
"      Tylenol&reg; Cold Head Congestion Daytime [OTC];",
"     </li>",
"     <li>",
"      Tylenol&reg; Cold Multi-Symptom Daytime [OTC];",
"     </li>",
"     <li>",
"      Vicks&reg; DayQuil&reg; Cold &amp; Flu Multi-Symptom [OTC];",
"     </li>",
"     <li>",
"      Vicks&reg; Nature Fusion&trade; Cold &amp; Flu Multi-Symptom Relief [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F5093666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Analgesic, Miscellaneous;",
"     </li>",
"     <li>",
"      Antitussive;",
"     </li>",
"     <li>",
"      Decongestant",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F5093687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Product labeling:",
"     </b>",
"     Relief of cold and flu symptoms: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alka-Seltzer Plus&reg; Day Cold, Comtrex&reg; Maximum Strength, Non-Drowsy Cold &amp; Cough; Theraflu Warming Relief&reg; Daytime Multi-Symptom Cold; Tylenol&reg; Cold Head Congestion Daytime: Two caplets/capsules every 4 hours (maximum: 6 doses/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theraflu&reg; Daytime Severe Cold &amp; Cough: One packet every 4 hours (maximum: 6 doses/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theraflu Warming Relief&reg; Daytime Severe Cold &amp; Cough: 30 mL every 4 hours (maximum: 6 doses/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tylenol&reg; Cold Multi-Symptom Daytime: Two caplets/gelcaps or 30 mL every 4 hours (maximum: 6 doses/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vicks&reg; DayQuil&reg; Cold &amp; Flu Multi-Symptom LiquiCaps: Two capsules every 4 hours (maximum: 4 doses/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vicks&reg; DayQuil&reg; Cold &amp; Flu Multi-Symptom Liquid: 30 mL every 4 hours (maximum: 4 doses/24 hours)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F5093686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Product labeling:",
"     </b>",
"     Relief of cold and flu symptoms: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vicks&reg; DayQuil&reg; Cold &amp; Flu Multi-Symptom Liquid:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 6-11 years: 15 mL every 4 hours (maximum: 4 doses/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alka-Seltzer Plus&reg; Day Cold, Comtrex&reg; Maximum Strength, Non-Drowsy Cold &amp; Cough Relief, Theraflu&reg; Daytime Severe Cold &amp; Cough, Theraflu Warming Relief&reg; Daytime Multi-Symptom Cold, Theraflu Warming Relief&reg; Daytime Severe Cold &amp; Cough, Tylenol&reg; Cold Head Congestion Daytime, Tylenol&reg; Cold Multi-Symptom Daytime, Vicks&reg; DayQuil&reg; Cold &amp; Flu Multi-Symptom LiquiCaps: Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F5093688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F5093692\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Caplet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Comtrex&reg; Maximum Strength, Non-Drowsy Cold &amp; Cough: Acetaminophen 325 mg, dextromethorphan hydrobromide 10 mg, and phenylephrine hydrochloride 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Mapap&reg; Multi-Symptom Cold: Acetaminophen 325 mg, dextromethorphan hydrobromide 10 mg, and phenylephrine hydrochloride 5 mg [cool blast flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Theraflu Warming Relief&reg; Daytime Multi-Symptom Cold: Acetaminophen 325 mg, dextromethorphan hydrobromide 10 mg, and phenylephrine hydrochloride 5 mg [contains menthol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Tylenol&reg; Cold Head Congestion Daytime: Acetaminophen 325 mg, dextromethorphan hydrobromide 10 mg, and phenylephrine hydrochloride 5 mg [Cool Burst&reg; flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Tylenol&reg; Cold Multi-Symptom Daytime: Acetaminophen 325 mg, dextromethorphan hydrobromide 10 mg, and phenylephrine hydrochloride 5 mg [Cool Burst&reg; flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Vicks&reg; Nature Fusion&trade; Cold &amp; Flu Multi-Symptom Relief: Acetaminophen 325 mg, dextromethorphan hydrobromide 10 mg, and phenylephrine hydrochloride 5 mg [ethanol free, gluten free; honey flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capsule, liquid filled, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Alka-Seltzer Plus&reg; Day Cold: Acetaminophen 325 mg, dextromethorphan hydrobromide 10 mg, and phenylephrine hydrochloride 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Daytime Cold &amp; Flu Relief Multi-Symptom [DSC]: Acetaminophen 325 mg, dextromethorphan hydrobromide 10 mg, and phenylephrine hydrochloride 5 mg [ethanol free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Vicks&reg; DayQuil&reg; Cold &amp; Flu Multi-Symptom: Acetaminophen 325 mg, dextromethorphan hydrobromide 10 mg, and phenylephrine hydrochloride 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gelcap, rapid release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Tylenol&reg; Cold Multi-Symptom Daytime: Acetaminophen 325 mg, dextromethorphan hydrobromide 10 mg, and phenylephrine hydrochloride 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Liquid, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Tylenol&reg; Cold Multi-Symptom Daytime: Acetaminophen 325 mg, dextromethorphan hydrobromide 10 mg, and phenylephrine hydrochloride 5 mg per 15 mL (240 mL) [contains propylene glycol, sodium 5 mg/15 mL, sodium benzoate; Citrus Burst&trade; flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Vicks&reg; DayQuil&reg; Cold &amp; Flu Multi-Symptom: Acetaminophen 325 mg, dextromethorphan hydrobromide 10 mg, and phenylephrine hydrochloride 5 mg per 15 mL (180 mL, 300 mL) [ethanol free, sugar free; contains propylene glycol, sodium 50 mg/15 mL, sodium benzoate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Powder for solution, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Theraflu&reg; Daytime Severe Cold &amp; Cough: Acetaminophen 650 mg, dextromethorphan hydrobromide 20 mg, and phenylephrine hydrochloride 10 mg per packet (6s) [contains phenylalanine 14 mg/packet, potassium 10 mg/packet, and sodium 20 mg/packet; berry-green tea-menthol flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Syrup, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Theraflu Warming Relief&reg; Daytime Severe Cold &amp; Cough: Acetaminophen 325 mg, dextromethorphan hydrobromide 10 mg, and phenylephrine hydrochloride 5 mg per 15 mL (245.5 mL) [contains ethanol, propylene glycol, sodium 8 mg/15 mL, sodium benzoate; cherry flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F5093664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Caplet",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F5093690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Solid dosage forms should be swallowed whole; do not crush, chew or dissolve. Administer liquid capsule formulations with water. Powder formulations (one packet) should be dissolved in 8 oz hot water and then consumed within 10-15 minutes. If using microwave, add one packet to 8 oz of cool water and stir briskly before and after heating.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F5093668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Temporary relief of common cold and flu symptoms (eg, pain, fever, cough, congestion)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5118570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Duplicate therapy issues: This product contains acetaminophen, which may be a component of other combination products. Do not exceed the maximum recommended daily dose of acetaminophen.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F5093674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F5093669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to acetaminophen, dextromethorphan, phenylephrine, or any component of the formulation; concurrent use of MAO inhibitors or within 14 days of therapy; concurrent use with other products containing acetaminophen",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F5093670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Ethanol use: Use with caution in patients with alcoholic liver disease; consuming &ge;3 alcoholic drinks/day may increase the risk of liver damage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Use caution in patients with hepatic impairment; acetaminophen may cause severe hepatic toxicity with acute overdose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Elderly: Use with caution in the elderly; more likely to experience adverse reactions to sympathomimetics.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pediatrics: Use with caution in children; do not exceed pediatric dosing recommendations. If no recommendations exist on OTC labeling for patient&rsquo;s age, the product should",
"     <b>",
"      not",
"     </b>",
"     be administered without the guidance of a physician.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Phenylalanine: Some products may contain phenylalanine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Sodium: Some products may contain sodium; use with caution in sodium restricted patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Acetaminophen: Avoid or limit use of other acetaminophen-containing products; limit total acetaminophen dose to &lt;4 g/day (adults) or &lt;2.6 g/day (children &lt;12 years of age).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Self-medication (OTC use): Patients with hypertension, hyperthyroidism, liver disease, diabetes mellitus, cardiovascular disease, or prostatic hyperplasia should consult a physician prior to use. Patients with chronic cough (associated with COPD or smoking) and/or productive cough (eg, copious amounts of phlegm) should be evaluated by a healthcare provider prior to use. Products containing acetaminophen are not recommended in patients consuming &ge;3 alcoholic beverages/day; consult a physician. If pain, nasal congestion, or cough increases in severity or persists &gt;7 days in adults (or &gt;5 days in children) during use, discontinue use and consult a physician. If redness, swelling, or rash occurs or if fever worsens or persists &gt;3 days during therapy, discontinue use and consult a physician. If sore throat is severe, accompanied by fever, headache, rash, nausea, or vomiting, or lasts &gt;2 days, consult a physician.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F5093678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F5093677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Alpha1-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha1-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha1-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: Alpha1-Agonists may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: May enhance the vasoconstricting effect of Phenylephrine (Systemic). Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of phenylephrine.  Use of hyaluronidase for other purposes in patients receiving phenylephrine may be considered as clinically indicated.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Alpha1-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha1-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F5093681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Excessive intake of ethanol may increase the risk of acetaminophen-induced hepatotoxicity. Avoid ethanol or limit to &lt;3 drinks/day.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F5093689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products may contain phenylalanine, potassium, and/or sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16324141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Alka-Seltzer Pls Sinus &amp; Cough Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-5-325 mg (20): $5.58",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Alka-Seltzer Plus Day Cold/Flu Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-5-325 mg (20): $5.58",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Robitussin Cold+Flu Daytime Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-5-325 mg (20): $5.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Vicks DayQuil Cold &amp; Flu Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-5-325 mg (24): $7.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (666 Cold Preparation Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-5-325 mg/15 mL (118 mL): $5.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Theraflu Warming Relief Day Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-5-325 mg/15 mL (245.5 mL): $4.39",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Vicks DayQuil Cold &amp; Flu Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-5-325 mg/15 mL (236 mL): $6.67",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Wal-Flu Severe Cold &amp; Cough Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-5-325 mg/15 mL (245 mL): $7.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pack",
"     </b>",
"     (Theraflu Severe Cold/Cgh Day Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20-10-650 mg (6): $4.61",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Tylenol Childrens Plus Cld/Cgh Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-2.5-160 mg/5 mL (120 mL): $5.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Comtrex Cold &amp; Cough Max St Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-5-325 mg (20): $4.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Mapap Cold Formula Multi-Sympt Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-5-325 mg (24): $2.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Sinadrin PE Complete Sinus Rel Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2-10-650 mg (30): $4.74",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Theraflu Severe Cold Daytime Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15-5-325 mg (24): $4.39",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Theraflu Severe Cold/Cgh Day Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-5-325 mg (24): $4.61",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Theraflu Warming Relief Cold Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-5-325 mg (24): $4.61",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Tylenol Cold Multi-Symptom Day Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-5-325 mg (24): $4.78",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     325-10-5 mg (24): $5.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Vicks Nature Fusion Cold &amp; Flu Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-5-325 mg (40): $12.62",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Tusedex (PH)",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Antlitz AM, Mead JA Jr, and Tolentino MA, &ldquo;Potentiation of Oral Anticoagulant Therapy by Acetaminophen,&rdquo;",
"      <i>",
"       Curr Ther Res Clin Exp",
"      </i>",
"      , 1968, 10(10):501-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/5/4182/abstract-text/4971464/pubmed\" id=\"4971464\" target=\"_blank\">",
"        4971464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bagheri H, Bernhard NB, and Montastruc JL, &ldquo;Potentiation of the Acenocoumarol Anticoagulant Effect by Acetaminophen,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1999, 33(4):506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/5/4182/abstract-text/10332548/pubmed\" id=\"10332548\" target=\"_blank\">",
"        10332548",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bartle WR and Blakely JA, &ldquo;Potentiation of Warfarin Anticoagulation by Acetaminophen,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1991, 265(10):1260.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/5/4182/abstract-text/1995971/pubmed\" id=\"1995971\" target=\"_blank\">",
"        1995971",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boeijinga JJ, Boerstra EE, Ris P, et al, &ldquo;Interaction Between Paracetamol and Coumarin Anticoagulants,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1982, 1(8270):506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/5/4182/abstract-text/6121161/pubmed\" id=\"6121161\" target=\"_blank\">",
"        6121161",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gadisseur AP, Van Der Meer FJ, and Rosendaal FR, &ldquo;Sustained Intake of Paracetamol (Acetaminophen) During Oral Anticoagulant Therapy With Coumarins Does Not Cause Clinically Important INR Changes: A Randomized Double-Blind Clinical Trial,&rdquo;",
"      <i>",
"       J Thromb Haemost",
"      </i>",
"      , 2003, 1(4):714-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/5/4182/abstract-text/12871405/pubmed\" id=\"12871405\" target=\"_blank\">",
"        12871405",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gebauer MG, Nyfort-Hansen K, Henschke PJ, et al, &ldquo;Warfarin and Acetaminophen Interaction,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2003, 23(1):109-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/5/4182/abstract-text/12523469/pubmed\" id=\"12523469\" target=\"_blank\">",
"        12523469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hylek EM, Heiman H, Skates SJ, et al, &ldquo;Acetaminophen and Other Risk Factors for Excessive Warfarin Anticoagulation,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1998, 279(9):657-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/5/4182/abstract-text/9496982/pubmed\" id=\"9496982\" target=\"_blank\">",
"        9496982",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kwan D, Bartle WR, and Walker SE, &ldquo;The Effects of Acute and Chronic Acetaminophen Dosing on the Pharmacodynamics and Pharmacokinetics of (R)- and (S)-Warfarin,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1995, 57:212.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rubin RN, Mentzer RL, and Budzynski AZ, \"Potentiation of Anticoagulant Effect of Warfarin by Acetaminophen (Tylenol&reg;),\"",
"      <i>",
"       Clin Res",
"      </i>",
"      , 1984, 32:698a.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van den Bemt PM, Geven LM, Kuitert NA, et al, \"The Potential Interaction Between Oral Anticoagulants and Acetaminophen in Everyday Practice,\"",
"      <i>",
"       Pharm World Sci",
"      </i>",
"      , 2002, 24(5):201-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/5/4182/abstract-text/12426965/pubmed\" id=\"12426965\" target=\"_blank\">",
"        12426965",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9292 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-FC5DC09734-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_5_4182=[""].join("\n");
var outline_f4_5_4182=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5093662\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5093666\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5093687\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5093686\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5093688\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5093692\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5093664\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5093690\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5093668\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5118570\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5093674\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5093669\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5093670\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5093678\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5093677\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5093681\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5093689\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16324141\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038896\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9292\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9292|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/54/30565?source=related_link\">",
"      Acetaminophen, dextromethorphan, and phenylephrine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_5_4183="Treatment of refractory and relapsed small cell lung cancer";
var content_f4_5_4183=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of refractory and relapsed small cell lung cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/5/4183/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/5/4183/contributors\">",
"     Karen Kelly, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/5/4183/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/5/4183/contributors\">",
"     Rogerio C Lilenbaum, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/5/4183/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/5/4183/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/5/4183/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small cell lung cancer (SCLC) represents 15 percent of all lung cancers and occurs almost exclusively in smokers. It is distinguished from non-small cell lung cancer by its rapid doubling time, high growth fraction, and the early development of widespread metastases. Although considered highly responsive to chemotherapy and radiotherapy, SCLC usually recurs within two years. Many of these patients are candidates for additional systemic treatment.",
"   </p>",
"   <p>",
"    The median survival of patients with relapsed SCLC ranges from two to six months. The most important factors affecting prognosis are performance status, tumor extent (ie, limited versus extensive), and time to relapse after first-line therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4183/abstract/1\">",
"     1",
"    </a>",
"    ]. Similarly, the likelihood of an objective response to second line therapy depends upon the time from last therapy to relapse, the response to initial treatment, and the performance status.",
"   </p>",
"   <p>",
"    The treatment of relapsed and refractory SCLC will be reviewed here. The initial management of SCLC and experimental approaches to treatment are considered separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/39/6778?source=see_link\">",
"     \"First-line chemotherapy for patients with extensive stage small cell lung cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9914?source=see_link\">",
"     \"Chemoradiotherapy for the initial treatment of limited stage small cell lung cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8951?source=see_link\">",
"     \"Experimental approaches to treatment for small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS OF RELAPSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with disease progression during or after their initial treatment are classified into one of the following categories representing different degrees of chemo sensitivity to guide treatment decision making.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sensitive relapse &ndash; Tumor progression occurs 90 days or more after the last day of initial treatment.",
"     </li>",
"     <li>",
"      Resistant relapse &ndash; Tumor progression occurs within 90 days after the last day of initial treatment.",
"     </li>",
"     <li>",
"      Refractory &ndash; Tumor progresses during the initial therapy or did not respond to initial therapy. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4085278\">",
"    <span class=\"h1\">",
"     SECOND LINE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptom control and improved quality of life are the primary goals of treatment, and these must be clear to both patients and their families.",
"   </p>",
"   <p>",
"    Second-line chemotherapy generally is less effective than the initial treatment, but it can provide significant palliation for many patients. Prolonged survival, increased time to tumor progression, and a reduction in tumor burden may also be achieved. Patients with sensitive relapse have the greatest potential to benefit from second line therapy while patients with resistant or refractory relapse are unlikely to respond to subsequent treatments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Chemotherapy versus best supportive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two phase III trials have compared chemotherapy with best supportive care (BSC) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4183/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one trial, 141 relapsed patients who were not candidates for intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/2/32807?source=see_link\">",
"       topotecan",
"      </a>",
"      received oral topotecan (2.3",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      daily for 5 days every 3 weeks) or BSC [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4183/abstract/2\">",
"       2",
"      </a>",
"      ]. All patients had relapsed &ge;45 days after achieving a response to first line therapy. Overall survival was significantly improved for patients receiving topotecan compared with BSC (26 weeks vs 14 weeks). A subgroup analysis showed that patients who relapsed &le;60 days after initial treatment benefited from treatment while patients who relapsed &ge;60 days showed a trend toward benefit with topotecan. Quality of life parameters also favored active intervention. An objective response was observed in 7 percent of patients; an additional 44 percent had stable disease, demonstrating the clinical importance of achieving stable disease.",
"     </li>",
"     <li>",
"      In another trial, 401 patients were randomly assigned to picoplatin, a novel platinum compound designed to overcome platinum resistance, or to BSC [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4183/abstract/3\">",
"       3",
"      </a>",
"      ]. Patients either had refractory disease or had relapsed within six months of a platinum regimen. There was no overall survival benefit for the patients receiving picoplatin compared with BSC (median survival 21 versus 20 weeks). However, survival was significantly prolonged with picoplatin in the subgroup of 294 patients with refractory disease or who relapsed within 45 days of treatment (21.3 versus 18.4 weeks for BSC). Picoplatin is not commercially available.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4085514\">",
"    <span class=\"h1\">",
"     SINGLE AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous cytotoxic agents have activity in relapsed SCLC, the most important of which is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/2/32807?source=see_link\">",
"     topotecan",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4085535\">",
"    <span class=\"h2\">",
"     Topotecan",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral and intravenous formulations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/2/32807?source=see_link\">",
"     topotecan",
"    </a>",
"    have been extensively evaluated for the second-line treatment of relapsed SCLC [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4183/abstract/2,4-6\">",
"     2,4-6",
"    </a>",
"    ]. Topotecan has been shown to increase survival compared with best supportive care [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4183/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Chemotherapy versus best supportive care'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The role of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/2/32807?source=see_link\">",
"     topotecan",
"    </a>",
"    in relapsed SCLC compared with alternative regimens is illustrated in a trial in which 211 patients who had relapsed &ge;60 days after completion of first-line therapy (usually platinum plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ) were randomly assigned to intravenous topotecan or a combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    (CAV) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4183/abstract/4\">",
"     4",
"    </a>",
"    ]. The overall response rates (24 versus 18 percent), median time to progression (13 versus 12 weeks), and median survival (25.0 versus 24.7 weeks) were similar in the two groups. The topotecan group had better control of several symptoms, including dyspnea, anorexia, hoarseness, and fatigue. Severe neutropenia was significantly less common with topotecan (38 versus 51 percent), but grade 3 or 4 thrombocytopenia and anemia occurred more frequently (9.8 versus 1.4 percent and 17.7 versus 7.2 percent, respectively). The improvement in symptom control lead to its FDA approval.",
"   </p>",
"   <p>",
"    The oral formulation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/2/32807?source=see_link\">",
"     topotecan",
"    </a>",
"    appears to have similar antitumor efficacy and tolerability compared with the IV formulation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4183/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. In a phase III noninferiority trial, 304 patients with chemosensitive relapse of SCLC were randomly assigned to oral (2.3",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    daily for five days) or IV (1.5",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    daily for five days) topotecan every three weeks. Response rates were similar (18 versus 22 percent) as were median and one-year survival rates (33 versus 35 weeks and 33 versus 29 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4183/abstract/6\">",
"     6",
"    </a>",
"    ]. The toxicity profiles of the two regimens were similar as well.",
"   </p>",
"   <p>",
"    The utility of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/2/32807?source=see_link\">",
"     topotecan",
"    </a>",
"    for relapsed SCLC is not dependent upon age. In a retrospective analysis of four observational studies and a randomized trial, there were 161 patients &ge;65 and 319 &lt;65 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4183/abstract/7\">",
"     7",
"    </a>",
"    ]. The objective response rate was the same in the two groups (14 versus 15 percent). The incidence, severity, and duration of grade 4 hematologic toxicities in the elderly were also similar (anemia 4 versus 3 percent in patients &lt;65 years, neutropenia 77 versus 72 percent, and thrombocytopenia 35 versus 24 percent).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/2/32807?source=see_link\">",
"     Topotecan",
"    </a>",
"    also has activity against brain metastases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/13/217?source=see_link&amp;anchor=H5#H5\">",
"     \"Systemic therapy for brain metastases\", section on 'small cell lung cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4085734\">",
"    <span class=\"h2\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other agents have modest activity in patients with relapsed SCLC. The evidence for activity of these agents comes from small, single arm phase II trials conducted ten or more years ago. These agents may represent an option for patients who are not candidates for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/2/32807?source=see_link\">",
"     topotecan",
"    </a>",
"    because of concerns about toxicity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    for patients with resistant relapse occurring &lt;45 days or refractory relapse for which there is no standard treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4085748\">",
"    <span class=\"h3\">",
"     Irinotecan",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"     Irinotecan",
"    </a>",
"    is primarily administered in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    as a first line treatment (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/39/6778?source=see_link&amp;anchor=H11#H11\">",
"     \"First-line chemotherapy for patients with extensive stage small cell lung cancer\", section on 'Camptothecin-based regimens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Three small clinical trials have evaluated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    as second line therapy, with objective response rates ranging from 16 to 47 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4183/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. As an example, in one study, 44 patients (17 with sensitive relapse and 27 with resistant or refractory disease) were treated with irinotecan 125",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    weekly times four with a two week break. The overall objective response rate was 16 percent. The response rate was 35 percent in the patients with sensitive relapse with a median survival of 6.8 months. The response rate in patients with resistant or refractory disease was 4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4183/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4085827\">",
"    <span class=\"h3\">",
"     Paclitaxel",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a study of 24 patients with refractory disease,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    (175",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every 21 days) resulted in seven partial responses (29 percent). However, the duration of response was generally brief (median 100 days), and there were four toxic deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4183/abstract/11\">",
"     11",
"    </a>",
"    ]. Another study evaluated 21 patients using paclitaxel 80",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    weekly for six of eight weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4183/abstract/12\">",
"     12",
"    </a>",
"    ]. Objective responses were seen in 3 of 11 patients with sensitive relapse and 2 of 10 patients with refractory relapse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4085864\">",
"    <span class=\"h3\">",
"     Docetaxel",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thirty-four previously treated patients (28 of whom were assessable for response), treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every three weeks) resulted in seven PRs (overall response rate 25 percent) with grade 4 neutropenia in 71 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4183/abstract/13\">",
"     13",
"    </a>",
"    ]. In a smaller study of 10 patients docetaxel was administered at 60-70",
"    <span class=\"nowrap\">",
"     mg/m2.",
"    </span>",
"    The objective response rate was 30 percent with all responses seen in patients with sensitive relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4183/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4085902\">",
"    <span class=\"h3\">",
"     Oral etoposide",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Hoosier Oncology Group evaluated oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    (50",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    daily) in 26 patients with refractory SCLC, 96 percent of whom were previously treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and IV etoposide [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4183/abstract/15\">",
"     15",
"    </a>",
"    ]. &nbsp;An overall response rate of 23 percent was obtained (one CR, five PR). Neutropenia was the dose-limiting toxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4085944\">",
"    <span class=\"h3\">",
"     Vinorelbine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two phase II studies evaluated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/59/953?source=see_link\">",
"     vinorelbine",
"    </a>",
"    (30",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    weekly) in a total of 60 patients with sensitive relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4183/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. The response rates were 16 and 15 percent respectively, with one of the studies reporting a median survival of 5 months. One additional study conducted in 24 relapsed or refractory SCLC patients using a dose of 25",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    weekly reported a response rate of 12.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4183/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4086003\">",
"    <span class=\"h3\">",
"     Gemcitabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited single agent activity has been seen with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4183/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. In a phase II study from the Eastern Cooperative Oncology Group, 46 patients with relapsed or refractory disease were treated with gemcitabine (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on days 1, 8, and 15 of each 28 day cycle) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4183/abstract/19\">",
"     19",
"    </a>",
"    ]. The objective response rate was 12 percent, but median survival was 7.1 months. A second study evaluated 1250",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    in 26 sensitive and 20",
"    <span class=\"nowrap\">",
"     resistant/refractory",
"    </span>",
"    patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4183/abstract/20\">",
"     20",
"    </a>",
"    ]. The response rates were 16 and 6 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4086068\">",
"    <span class=\"h3\">",
"     Amrubicin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amrubicin is a synthetic anthracycline that is available only in Japan. In a phase III trial, 637 patients with sensitive, resistant or refractory relapse were randomly assigned in a 2:1 fashion to amrubicin (40",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    days 1 to 3 every three weeks) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/2/32807?source=see_link\">",
"     topotecan",
"    </a>",
"    (1.5",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    IV days 1-5 every three weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4183/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There was no difference in overall survival (7.5 months for amrubicin and 7.8 months for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/2/32807?source=see_link\">",
"     topotecan",
"    </a>",
"    ). Response rate and progression-free survival significantly favored amrubicin. Symptom control and quality of life were also better for patients receiving amrubicin. In terms of toxicity, amrubicin was associated with a higher infection and febrile neutropenia rate than topotecan but had less anemia, neutropenia and thrombocytopenia.",
"   </p>",
"   <p>",
"    In patients with resistant or refractory SCLC a significant improvement in overall survival was seen for amrubicin (median 6.2 versus 5.7 months with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/2/32807?source=see_link\">",
"     topotecan",
"    </a>",
"    , HR 0.77).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H184702\">",
"    <span class=\"h3\">",
"     Temozolomide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     Temozolomide",
"    </a>",
"    is an oral alkylating agent that is generally well tolerated. In a phase II study of 64 patients (48 with sensitive disease and 16 with refractory disease), one complete response and 10 partial responses were observed, for an overall objective response rate of 16 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4183/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H184730\">",
"    <span class=\"h3\">",
"     Bendamustine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/20/32071?source=see_link\">",
"     Bendamustine",
"    </a>",
"    , another alkylating agent, showed antitumor activity in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4183/abstract/23\">",
"     23",
"    </a>",
"    ]. Bendamustine is currently being studied in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    (NCT00856830).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4086093\">",
"    <span class=\"h1\">",
"     COMBINATION CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the availability of a number of modestly active single agents, combination chemotherapy regimens were evaluated to improve response rates and prolong survival. Although many phase II studies produced higher response rates than single agent chemotherapy, combination chemotherapy was associated with more toxicity and is not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4183/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4086119\">",
"    <span class=\"h1\">",
"     REINDUCTION WITH THE SAME REGIMEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reinduction with the same chemotherapy regimen used for initial treatment may result in a response in patients with a late relapse and should be considered in patients with prolonged time to relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4183/abstract/25-29\">",
"     25-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Support for this strategy comes from a multi-institutional, retrospective analysis of European patients who received second line chemotherapy from 1999 to 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4183/abstract/29\">",
"     29",
"    </a>",
"    ]. Thirty of the 161 patients were retreated with the same platinum regimen. A clinical benefit for retreatment regardless of the time to relapse was seen but the highest benefit was observed in patients whose relapse occurred at 12 months or beyond.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4086353\">",
"    <span class=\"h1\">",
"     BRAIN METASTASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple reports indicate that intracranial metastases from SCLC are responsive to chemotherapy. Furthermore, chemotherapy may be additive to the effects of whole brain radiation therapy in the management of brain metastases.",
"   </p>",
"   <p>",
"    The use of chemotherapy in the management of brain metastases is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/13/217?source=see_link&amp;anchor=H5#H5\">",
"     \"Systemic therapy for brain metastases\", section on 'small cell lung cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/38/24162?source=see_link\">",
"       \"Patient information: Small cell lung cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?22/8/22659?source=see_link\">",
"       \"Patient information: Small cell lung cancer treatment (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who relapse &ge;45 days after treatment with their initial chemotherapy regimen, we recommend second line chemotherapy rather than best supportive care if their overall condition permits additional therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). This approach has been shown to improve overall survival. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Chemotherapy versus best supportive care'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest single agent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/2/32807?source=see_link\">",
"       topotecan",
"      </a>",
"      (either oral or intravenous) rather than combination chemotherapy or other single agents (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4085535\">",
"       'Topotecan'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who are not candidates for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/2/32807?source=see_link\">",
"       topotecan",
"      </a>",
"      , a number of other single agents may offer an alternative, although their benefit has not been established in randomized clinical trials (See",
"      <a class=\"local\" href=\"#H4085734\">",
"       'Other agents'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is no standard treatment for patients with refractory disease or who develop tumor progression &lt;45 days after completing their initial treatment regimen. Whenever possible, all patients with relapsed or refractory SCLC should be enrolled on a clinical trial. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8951?source=see_link\">",
"       \"Experimental approaches to treatment for small cell lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4183/abstract/1\">",
"      Albain KS, Crowley JJ, Livingston RB. Long-term survival and toxicity in small cell lung cancer. Expanded Southwest Oncology Group experience. Chest 1991; 99:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4183/abstract/2\">",
"      O'Brien ME, Ciuleanu TE, Tsekov H, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006; 24:5441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4183/abstract/3\">",
"      Ciuleanu T, Samarzjia M, Demidchik Y, et AL. Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first-line platinum-based chemotherapy. J Clin Oncol 2010; 28:515s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4183/abstract/4\">",
"      von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999; 17:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4183/abstract/5\">",
"      von Pawel J, Gatzemeier U, Pujol JL, et al. Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol 2001; 19:1743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4183/abstract/6\">",
"      Eckardt JR, von Pawel J, Pujol JL, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 2007; 25:2086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4183/abstract/7\">",
"      Garst J, Buller R, Lane S, Crawford J. Topotecan in the treatment of elderly patients with relapsed small-cell lung cancer. Clin Lung Cancer 2005; 7:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4183/abstract/8\">",
"      Masuda N, Fukuoka M, Kusunoki Y, et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1992; 10:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4183/abstract/9\">",
"      LeChevalier, T, Ibrahim, N, Chomy, P, et al. A phase II study of irinotecan in patients with small cell lung cancer progressing after initial response to first line chemotherapy (abstract). Proc Am Soc Clin Oncol 1997; 16:450a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4183/abstract/10\">",
"      DeVore, R, Blanke, C, Denham, C, et al. Phase II study of irinotecan in patients with previously treated small cell lung cancer (abstract). Proc Am Soc Clin Oncol 1998; 17:451a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4183/abstract/11\">",
"      Smit EF, Fokkema E, Biesma B, et al. A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. Br J Cancer 1998; 77:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4183/abstract/12\">",
"      Yamamoto N, Tsurutani J, Yoshimura N, et al. Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer. Anticancer Res 2006; 26:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4183/abstract/13\">",
"      Smyth JF, Smith IE, Sessa C, et al. Activity of docetaxel (Taxotere) in small cell lung cancer. The Early Clinical Trials Group of the EORTC. Eur J Cancer 1994; 30A:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4183/abstract/14\">",
"      Nakamura, H, Azuma, M, Miyagi, K, et al. A pilot study of docetaxel as salvage chemotherapy in small cell lung cancer (abstract). Proc Am Soc Clin Oncol 2001; 20:280b.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4183/abstract/15\">",
"      Einhorn LH, Pennington K, McClean J. Phase II trial of daily oral VP-16 in refractory small cell lung cancer: a Hoosier Oncology Group study. Semin Oncol 1990; 17:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4183/abstract/16\">",
"      Jassem J, Karnicka-Modkowska H, van Pottelsberghe C, et al. Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients. EORTC Lung Cancer Cooperative Group. Eur J Cancer 1993; 29A:1720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4183/abstract/17\">",
"      Lake D, Johnson E, Kawahara M, et al. Phase II trial of Navelbine (NVB) in relapsed small cell lung cancer (SCLC) (abstract #1703). J Clin Oncol 1997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4183/abstract/18\">",
"      Furuse K, Kubota K, Kawahara M, et al. Phase II study of vinorelbine in heavily previously treated small cell lung cancer. Japan Lung Cancer Vinorelbine Study Group. Oncology 1996; 53:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4183/abstract/19\">",
"      Masters GA, Declerck L, Blanke C, et al. Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597. J Clin Oncol 2003; 21:1550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4183/abstract/20\">",
"      Hoang T, Kim K, Jaslowski A, et al. Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer. Lung Cancer 2003; 42:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4183/abstract/21\">",
"      Jotte R, Von Pawel J, Spigel DR, et al. Randomized phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small cell lung cancer SCLC (abstract #7000). J Clin Oncol 2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4183/abstract/22\">",
"      Pietanza MC, Kadota K, Huberman K, et al. Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker. Clin Cancer Res 2012; 18:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4183/abstract/23\">",
"      K&ouml;ster W, Stamatis G, Heider A, et al. Carboplatin in Combination with Bendamustine in Previously Untreated Patients with Extensive-Stage Small Cell Lung Cancer (SCLC). Clin Drug Investig 2004; 24:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4183/abstract/24\">",
"      Nair BS, Bhanderi V, Jafri SH. Current and emerging pharmacotherapies for the treatment of relapsed small cell lung cancer. Clin Med Insights Oncol 2011; 5:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4183/abstract/25\">",
"      Postmus PE, Berendsen HH, van Zandwijk N, et al. Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy. Eur J Cancer Clin Oncol 1987; 23:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4183/abstract/26\">",
"      Batist G, Ihde DC, Zabell A, et al. Small-cell carcinoma of lung: reinduction therapy after late relapse. Ann Intern Med 1983; 98:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4183/abstract/27\">",
"      Giaccone G, Ferrati P, Donadio M, et al. Reinduction chemotherapy in small cell lung cancer. Eur J Cancer Clin Oncol 1987; 23:1697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4183/abstract/28\">",
"      Collard P, Weynants P, Francis C, Rodenstein DO. Treatment of relapse of small cell lung cancer in selected patients with the initial combination chemotherapy carboplatin, etoposide, and epirubicin. Thorax 1992; 47:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4183/abstract/29\">",
"      Garassino MC, Torri V, Michetti G, et al. Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis. Lung Cancer 2011; 72:378.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4614 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-528937E1C1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_5_4183=[""].join("\n");
var outline_f4_5_4183=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS OF RELAPSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4085278\">",
"      SECOND LINE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Chemotherapy versus best supportive care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4085514\">",
"      SINGLE AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4085535\">",
"      Topotecan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4085734\">",
"      Other agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4085748\">",
"      - Irinotecan",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4085827\">",
"      - Paclitaxel",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4085864\">",
"      - Docetaxel",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4085902\">",
"      - Oral etoposide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4085944\">",
"      - Vinorelbine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4086003\">",
"      - Gemcitabine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4086068\">",
"      - Amrubicin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H184702\">",
"      - Temozolomide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H184730\">",
"      - Bendamustine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4086093\">",
"      COMBINATION CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4086119\">",
"      REINDUCTION WITH THE SAME REGIMEN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4086353\">",
"      BRAIN METASTASES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9914?source=related_link\">",
"      Chemoradiotherapy for the initial treatment of limited stage small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8951?source=related_link\">",
"      Experimental approaches to treatment for small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/39/6778?source=related_link\">",
"      First-line chemotherapy for patients with extensive stage small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/38/24162?source=related_link\">",
"      Patient information: Small cell lung cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/8/22659?source=related_link\">",
"      Patient information: Small cell lung cancer treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/13/217?source=related_link\">",
"      Systemic therapy for brain metastases",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_5_4184="Electrocardiographic abnormalities and conduction disturbances in athletes";
var content_f4_5_4184=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Electrocardiographic abnormalities and conduction disturbances in athletes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/5/4184/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/5/4184/contributors\">",
"     Mark S Link, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/5/4184/contributors\">",
"     Antonio Pelliccia, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/5/4184/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/5/4184/contributors\">",
"     Peter J Zimetbaum, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/5/4184/contributors\">",
"     Ary L Goldberger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/5/4184/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/5/4184/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/5/4184/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arrhythmias are frequently documented in athletes and can be a source of morbidity and mortality, particularly ventricular tachyarrhythmias and sudden cardiac death (SCD). The two primary goals when evaluating athletes for electrocardiographic (ECG) abnormalities are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To document the presence of arrhythmia and underlying structural heart disease that place the athlete at risk for SCD",
"     </li>",
"     <li>",
"      To evaluate the importance of an arrhythmia in assessing the athlete's eligibility for competition",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic will discuss electrocardiographic abnormalities and conduction disturbances and their importance in athletes. The risk of sudden death in athletes, particularly those with underlying heart disease, and the management of arrhythmia in athletes are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/37/31318?source=see_link\">",
"     \"Screening to prevent sudden cardiac death in athletes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13898?source=see_link\">",
"     \"Risk of sudden cardiac death in athletes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23192?source=see_link\">",
"     \"Arrhythmia in athletes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVALENCE AND ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A broad range of electrocardiographic (ECG) abnormalities can be seen in trained athletes. The type of abnormality and whether the abnormality is related or unrelated to training impacts the decision regarding further evaluation and participation in athletics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2027794\">",
"    <span class=\"h2\">",
"     Frequency of ECG abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;One report of 1005 athletes evaluated with ECG and echocardiography found what were labeled as distinctly abnormal ECG patterns in 14 percent, while a mildly abnormal ECG pattern was seen in 26 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4184/abstract/1\">",
"     1",
"    </a>",
"    ]. Sixty percent had an ECG that was normal or had minor alterations, and structural abnormalities were documented by echocardiography in only 5 percent.",
"   </p>",
"   <p>",
"    Distinct ECG abnormalities (14 percent) included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      R or S wave &ge;35 mm (left ventricular hypertrophy by traditional criteria) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/13/3285?source=see_link\">",
"       \"Electrocardiographic diagnosis of left ventricular hypertrophy\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Negative T wave (except V1, VR and lead III)",
"     </li>",
"     <li>",
"      Q wave &ge;4 mm in depth",
"     </li>",
"     <li>",
"      Left axis deviation (over -35&deg;)",
"     </li>",
"     <li>",
"      Right axis deviation (&gt;110&deg;)",
"     </li>",
"     <li>",
"      Wolff-Parkinson-White syndrome (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/61/17370?source=see_link&amp;anchor=H13260510#H13260510\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of the Wolff-Parkinson-White syndrome\", section on 'Electrocardiographic (ECG) findings'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Left bundle branch block (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39784?source=see_link\">",
"       \"Left bundle branch block\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Mild ECG abnormalities (26 percent) included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      R or S wave 30 to 34 mm",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Flat/tall",
"      </span>",
"      T wave diffuse in &gt;2 leads",
"     </li>",
"     <li>",
"      Q wave 2 to 3 mm",
"     </li>",
"     <li>",
"      Left atrial or right atrial enlargement (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27204?source=see_link\">",
"       \"ECG tutorial: Chamber enlargement and hypertrophy\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Incomplete R wave progression V1 to V3",
"     </li>",
"     <li>",
"      PR interval &le;0.12 sec",
"     </li>",
"     <li>",
"      Right bundle branch block (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10344?source=see_link\">",
"       \"Right bundle branch block\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Minor and non-pathological alterations (including normal variants) on the ECG included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      R or S wave 25 to 29 mm",
"     </li>",
"     <li>",
"      Early repolarization (J point elevation) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/38/38505?source=see_link\">",
"       \"Early repolarization\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Incomplete right bundle branch block",
"     </li>",
"     <li>",
"      PR interval &gt;0.20 sec",
"     </li>",
"     <li>",
"      Sinus bradycardia (&lt;60 bpm) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/50/3878?source=see_link\">",
"       \"Sinus bradycardia\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Apparently abnormal ECG patterns were associated with a larger left ventricular end-diastolic dimension and wall thickness and were more common in males, in athletes of a younger age, and in athletes who engaged in endurance sports (eg, cycling, rowing, cross-country skiing). A vast majority of the ECG abnormalities are related to increased",
"    <span class=\"nowrap\">",
"     R/S",
"    </span>",
"    wave voltages, suggestive of left ventricular hypertrophy. Other abnormalities, such as repolarization abnormalities and primarily negative T waves, were relatively rare and unrelated to cardiac dimensions. Although negative T waves tend to normalize with exercise, this pattern does not imply an absence of structural cardiac diseases, and these ECG abnormalities not uncommonly have clinical or pathologic implications [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4184/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2027761\">",
"    <span class=\"h2\">",
"     Training-related versus training-unrelated ECG changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;For practical purposes, ECG changes in athletes can be separated into two groups (",
"    <a class=\"graphic graphic_table graphicRef83350 \" href=\"UTD.htm?43/22/44395\">",
"     table 1",
"    </a>",
"    ), depending on whether the ECG abnormality may be considered a result of chronic training or whether it occurs independently of training [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4184/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Training-related ECG abnormalities occur commonly and are not associated with an increased risk of underlying cardiac disease and incidence of adverse events during exercise. Athletes with training-related ECG abnormalities do not usually require additional evaluation and can continue to participate in athletics.",
"     </li>",
"     <li>",
"      In contrast, ECG abnormalities that are unrelated to training often occur secondary to an underlying pathologic disease process (eg, hypertrophic cardiomyopathy, Wolff-Parkinson-White syndrome, arrhythmogenic right ventricular cardiomyopathy, long QT syndrome). Training-unrelated ECG changes occur less frequently (&lt;5 percent) and potentially are an expression of underlying cardiac abnormality. They convey an increased risk associated with exercise.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Persons with training-unrelated ECG abnormalities should typically undergo additional cardiovascular testing and evaluation for clinically important cardiac pathology. There is significant overlap between training-related versus training-unrelated ECG changes. In addition, in some athletes the distinction between an athlete's heart and a pathologic condition is difficult, and gray areas will exist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H618639\">",
"    <span class=\"h1\">",
"     CONDUCTION ABNORMALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;ECG patterns suggestive of slowed AV nodal conduction (eg, first degree AV block and Mobitz type I second degree AV block) can result from increased vagal tone, which is normally seen as an adaptive response to certain types of athletic conditioning, particularly endurance training. No specific limitations are necessary in this setting as long as the athlete is asymptomatic and the conduction abnormalities improve (ie, disappear) with exertion. However, higher degrees of conduction abnormality will require attention prior to participation in athletics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     First degree AV block",
"    </span>",
"    &nbsp;&mdash;&nbsp;First degree atrioventricular (AV) block, characterized by prolongation of the PR interval (",
"    <a class=\"graphic graphic_waveform graphicRef67882 \" href=\"UTD.htm?11/45/11989\">",
"     waveform 1",
"    </a>",
"    ), is commonly seen in athletes and has no important implications. Usually it is accompanied by resting sinus bradycardia. If the QRS complex is normal and the athlete has not had symptoms of syncope or presyncope, only a 12 lead ECG is necessary. If the QRS complex is abnormal or the athlete has had symptoms of syncope or presyncope, we recommend a noninvasive evaluation including an exercise stress test, echocardiogram, and, in some patients, 24-hour ambulatory monitoring because of the potential for underlying structural heart disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41574?source=see_link\">",
"     \"First degree atrioventricular block\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Athletes with isolated first degree AV block who are asymptomatic and have no evidence for structural heart disease can participate in all sports [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4184/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The nature and severity of underlying heart disease can independently dictate other restrictions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Second degree AV block: Mobitz type I (Wenckebach)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mobitz type I (Wenckebach) second degree AV block, especially at rest or sleep, is often present in normal, well-conditioned athletes due to enhanced vagal tone (",
"    <a class=\"graphic graphic_waveform graphicRef73051 \" href=\"UTD.htm?42/35/43573\">",
"     waveform 2",
"    </a>",
"    ). In general, Mobitz type I (Wenckebach) second degree AV block has no important implications. However, in athletes with symptoms (eg, presyncope or syncope) possibly due to bradycardia, we recommend a noninvasive evaluation including an exercise stress test, echocardiogram, and, in some patients, 24-hour ambulatory monitoring because of the potential for underlying structural heart disease. Those athletes who also have a bundle branch block may require electrophysiologic testing to establish the location of the Wenckebach block. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/42/18087?source=see_link\">",
"     \"Second degree atrioventricular block: Mobitz type I (Wenckebach block)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Asymptomatic patients with Mobitz type I second degree AV block and no worsening or actual improvement of AV block with exercise or recovery can participate in all competitive sports (",
"    <a class=\"graphic graphic_figure graphicRef64493 \" href=\"UTD.htm?28/51/29489\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4184/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Asymptomatic athletes in whom Mobitz type I second degree AV block initially appears or worsens with exercise or during the recovery period may need further evaluation as worsening of Mobitz type I block with exercise would be highly unusual. (",
"    <a class=\"graphic graphic_figure graphicRef64493 \" href=\"UTD.htm?28/51/29489\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Second degree AV block: Mobitz type II",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mobitz type II second degree AV block (",
"    <a class=\"graphic graphic_waveform graphicRef79539 \" href=\"UTD.htm?28/37/29270\">",
"     waveform 3",
"    </a>",
"    ) is uncommon in athletes and, when present, usually is due to disease in the His-Purkinje system. The evaluation and treatment of Mobitz II AV block is usually considered to be similar to those athletes with complete AV block. In the absence of a potentially reversible condition (eg, Lyme carditis), Mobitz II AV block should be treated with a pacemaker before permitting any physical activity or sport activity [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4184/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/62/998?source=see_link\">",
"     \"Second degree atrioventricular block: Mobitz type II\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40759?source=see_link\">",
"     \"Lyme carditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Acquired complete AV block",
"    </span>",
"    &nbsp;&mdash;&nbsp;When acquired complete AV block (",
"    <a class=\"graphic graphic_waveform graphicRef72863 \" href=\"UTD.htm?20/42/21160\">",
"     waveform 4",
"    </a>",
"    ) is due to structural disease of the AV node, the escape rhythm is often junctional and has a narrow QRS complex. In contrast, the escape rhythm is ventricular with a wide QRS complex when complete AV block is due to structural disease of the His-Purkinje system (",
"    <a class=\"graphic graphic_waveform graphicRef51446 \" href=\"UTD.htm?28/52/29509\">",
"     waveform 5",
"    </a>",
"    ). In the absence of a potentially reversible condition (eg, Lyme carditis), this condition should be treated with a pacemaker before permitting any physical or sport activity [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4184/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15285?source=see_link\">",
"     \"Third degree (complete) atrioventricular block\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40759?source=see_link\">",
"     \"Lyme carditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Congenital complete AV block",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital complete AV block is due to disease in the AV node, often occurring in the absence of other structural cardiac abnormalities. Most patients have a narrow complex, junctional escape rhythm. Evaluation of athletes with this abnormality includes a 12 lead ECG, 24-hour ambulatory monitoring, an exercise test performed to the same exercise level as that during the sports activity, and an echocardiogram. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10376?source=see_link\">",
"     \"Congenital third degree (complete) atrioventricular block\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We agree that athletes with congenital heart block, a structurally normal heart and normal cardiac function, a narrow QRS complex, ventricular rates at rest greater than 40 to 50 beats per minute increasing appropriately with exertion (&gt;120 bpm), no history of syncope or near syncope, and no ventricular tachycardia during exertion can participate in competitive sports according to the most recently published expert consensus statement. [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4184/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. In contrast, athletes with ventricular arrhythmia, symptoms of fatigue, near-syncope, or syncope should have a pacemaker implanted before they participate in competitive sports.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Complete right or left bundle branch block",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete right bundle branch block (RBBB) (",
"    <a class=\"graphic graphic_waveform graphicRef64393 \" href=\"UTD.htm?42/12/43210\">",
"     waveform 6",
"    </a>",
"    ) is not uncommon among athletes and may be seen with or without underlying structural heart disease. Complete left bundle branch block (LBBB) (",
"    <a class=\"graphic graphic_waveform graphicRef61594 \" href=\"UTD.htm?42/28/43466\">",
"     waveform 7",
"    </a>",
"    ) is rarely seen and usually reflects underlying structural heart disease, mandating careful investigation for underlying cardiac abnormality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10344?source=see_link\">",
"     \"Right bundle branch block\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39784?source=see_link\">",
"     \"Left bundle branch block\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    RBBB and LBBB are generally not associated with symptoms. Evaluation of RBBB or LBBB in an athlete includes a 12 lead ECG, 24 hour ambulatory monitoring, and an echocardiogram. Athletes with asymptomatic RBBB or LBBB and no ventricular arrhythmias who do not develop AV block with exercise can participate in all competitive sports consistent with their cardiac status and existing recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4184/abstract/5\">",
"     5",
"    </a>",
"    ]. Periodic follow-up is, however, suggested for all individuals with complete LBBB to ascertain a possible incidence of symptoms or evidence for cardiac disease. There is no expert consensus or guideline recommendations regarding the frequency of follow-up, but we feel that in the absence of symptoms, one annual follow-up with repeat ECG and echocardiography is appropriate, with additional follow-up after one year to generally be determined by the development of symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2027923\">",
"    <span class=\"h3\">",
"     Screening of family members in the presence of bifascicular block",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of bifascicular block (LBBB, RBBB and left anterior fascicular block, RBBB and left posterior fascicular block) in a young, otherwise healthy athlete also raises the possibility of an inherited conduction system disease such as Len&egrave;gre disease, an autosomal dominant disorder that results in progressive conduction system dysfunction. First degree relatives of an athlete with bifascicular block on",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    ECG should be screened with an ECG to search for any evidence of conduction system disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4184/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32007?source=see_link&amp;anchor=H8#H8\">",
"     \"Etiology of atrioventricular block\", section on 'Familial disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H174699\">",
"    <span class=\"h2\">",
"     Athletes with pacemakers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Athletes with pacemakers should not participate in competitive sports when the danger of bodily collision exists because such trauma may damage the pacemaker system. Before allowing athletes to engage in these activities, an exercise test should be conducted at the level of activity demanded by the particular sport so as to be certain that the paced heart rate increases appropriately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2027821\">",
"    <span class=\"h1\">",
"     CONDITIONS WITH ECG ABNORMALITIES AND INCREASED RISK DURING EXERCISE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Arrhythmogenic right ventricular cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an entity involving fibrofatty infiltration of the right ventricular myocardium, predominantly the free wall that is associated with an increased risk of sudden cardiac death (SCD). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/62/23528?source=see_link\">",
"     \"Genetics and pathogenesis of arrhythmogenic right ventricular cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ARVC may be associated with characteristic or suggestive ECG findings, primarily localized to the right precordial leads. These include a QRS duration in V1 of more than 110 msec, an epsilon wave due to delayed activation across the right ventricular myocardium in leads V1 or V2, and T wave inversion in the right precordial leads (",
"    <a class=\"graphic graphic_waveform graphicRef60781 \" href=\"UTD.htm?41/5/42078\">",
"     waveform 8",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32106?source=see_link&amp;anchor=H10#H10\">",
"     \"Clinical manifestations and diagnosis of arrhythmogenic right ventricular cardiomyopathy\", section on '12-lead ECG'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among competitive athletes, ARVC is a cause of SCD, particularly in Italy where the disease may be more prevalent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4184/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. The current recommendation, due to lack of reliable criteria to stratify all patients for their arrhythmic risk and the real possibility that vigorous athletics may worsen the underlying disease, is that patients with ARVC should",
"    <strong>",
"     not",
"    </strong>",
"    participate in any moderate or high-intensity competitive sport [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4184/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13898?source=see_link\">",
"     \"Risk of sudden cardiac death in athletes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Brugada pattern type 1/syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Right precordial abnormalities on the ECG are also seen in Brugada syndrome, which, in its classic manifestation, is characterized by a pseudo-RBBB pattern and persistent ST segment elevation with coved type down-sloping ST-T waves in V1 to V3 (",
"    <a class=\"graphic graphic_waveform graphicRef64510 \" href=\"UTD.htm?8/35/8762\">",
"     waveform 9",
"    </a>",
"    ). Although Brugada syndrome, like ARVC, is associated with an increased risk of SCD, such events in patients with the Brugada pattern type 1 (ie, the Brugada syndrome) are typically not related to exercise, and Brugada syndrome has not been noted as a cause of SCD in athletes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4184/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28250?source=see_link\">",
"     \"Brugada syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, regular physical training can augment cardiac vagal activity and increase the relative risk for arrhythmic events during the recovery and resting periods. For this reason, we suggest restricting patients with Brugada type I pattern from competitive sport activities [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4184/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25707090\">",
"    <span class=\"h2\">",
"     Catecholaminergic polymorphic VT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Catecholaminergic polymorphic VT (CPVT), also known as familial catecholaminergic polymorphic VT, occurs in the absence of structural heart disease. Affected patients typically present with life-threatening VT (",
"    <a class=\"graphic graphic_waveform graphicRef54538 \" href=\"UTD.htm?7/6/7271\">",
"     waveform 10",
"    </a>",
"    ) or ventricular fibrillation (VF) during emotional or physical stress, with syncope often being the first manifestation of the disease.",
"   </p>",
"   <p>",
"    Participation in competitive athletics increases the risk of ventricular arrhythmias in patients with CPVT due to the rise in catecholamines associated with exertion. Therefore, we recommend that patients with CPVT avoid competitive sports and any vigorous activities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37641?source=see_link&amp;anchor=H6470945#H6470945\">",
"     \"Catecholaminergic polymorphic ventricular tachycardia and other polymorphic ventricular tachycardias with a normal QT interval\", section on 'Approach to treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25707098\">",
"    <span class=\"h2\">",
"     Hypertrophic cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertrophic cardiomyopathy (HCM), an autosomal dominant genetic disease of the cardiac sarcomere, is characterized by left ventricular hypertrophy (",
"    <a class=\"graphic graphic_waveform graphicRef69040 \" href=\"UTD.htm?41/58/42922\">",
"     waveform 11",
"    </a>",
"    ) of various morphologies, with a wide array of clinical manifestations and hemodynamic abnormalities, including fatigue, dyspnea, chest pain, palpitations, syncope, and SCD. Patients with HCM are prone to both atrial and ventricular arrhythmias, many of which are asymptomatic, but some can precipitate hemodynamic collapse and sudden cardiac death (SCD).",
"   </p>",
"   <p>",
"    Due to the risk of SCD associated with exercise in HCM patients, athletic activity restriction is an important component of patient management. Sport activity restriction in patients with HCM is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13898?source=see_link&amp;anchor=H13#H13\">",
"     \"Risk of sudden cardiac death in athletes\", section on 'Hypertrophic cardiomyopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25707291\">",
"    <span class=\"h2\">",
"     Long QT syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The calculation of the QT interval in athletes has limitations due to sinus arrhythmia, slightly widened QRS complexes, and T-U complexes. Corrections for heart rates may be inaccurate at heart rates &le;40 beats per minute and &gt;120 beats per minute. Recording QTc intervals beyond the normal cut off values should raise the suspicion of either acquired or congenital long QT syndrome (LQTS). The most frequent cause is the congenital long QT syndrome, which is a genetically-determined ion channel disease that may cause life-threatening ventricular arrhythmias such as torsades-de-pointes and ventricular fibrillation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2202?source=see_link\">",
"     \"Clinical features of congenital long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When an abnormally prolonged QTc interval is identified (",
"    <a class=\"graphic graphic_waveform graphicRef77018 \" href=\"UTD.htm?26/24/27008\">",
"     waveform 12",
"    </a>",
"    ), potential transient causes of acquired QT prolongation should be excluded. Athletes with QTc intervals between 440 msec and 500 msec represent a \"grey zone\", which requires detailed assessment to achieve a definitive diagnosis. Society guidelines regarding the management of athletes with prolonged QTc intervals are subtly different in the US and Europe:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The European Society of Cardiology states that unequivocal diagnosis of LQTS (regardless the specific gene abnormality responsible) is the basis for disqualification from competitive sports [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4184/abstract/5\">",
"       5",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      American recommendations from the 36",
"      <sup>",
"       th",
"      </sup>",
"      Bethesda conference are slightly more liberal as they allow asymptomatic patients with baseline QT prolongation (QTc of 470 ms or more in males, 480 ms or more in females) to participate in class IA sports. The restriction limiting participation to class IA activities may be further liberalized for the asymptomatic patient with genetically proven type 3 LQTS (LQT3) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4184/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given that the activity level associated with class IA sports is nearly the same as routine daily living, we generally allow patients with a prolonged QT interval to participate in such activities and restrict high levels of activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25707298\">",
"    <span class=\"h2\">",
"     Short QT syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Short QT syndrome (SQTS) is an inheritable ion channel disease that is characterized by an abnormally short cardiac repolarization (as noted by short QT interval on surface ECG) predisposing to life-threatening ventricular arrhythmias. Shortening of repolarization allows for short myocardial refractoriness, which predisposes to atrial or ventricular fibrillation in the absence of structural heart disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/61/19417?source=see_link\">",
"     \"Short QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When an abnormally short QTc interval is identified in an athlete (QTc &lt;380 msec), causes of transient QT shortening (such as hypercalcemia, hyperkalemia, hyperthermia, acidosis and some drugs [eg, digitalis, anabolic steroids]), must be ruled out. In the absence of acquired causes of short QT interval, the athlete should be referred for familial ECG-clinical screening and molecular genetic evaluation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/61/19417?source=see_link&amp;anchor=H1561601171#H1561601171\">",
"     \"Short QT syndrome\", section on 'Diagnostic evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is a lack of published literature regarding the risks of sudden cardiac death (SCD) in athletes with SQTS. However, because of the possibility of ventricular arrhythmias, as well as the extensive literature showing a high risk of SCD in athletes with other conditions associated with ventricular arrhythmias, we currently suggest restriction from most competitive sports when the diagnosis is confirmed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H982954947\">",
"    <span class=\"h2\">",
"     WPW syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular preexcitation (eg, Wolff-Parkinson-White syndrome [WPW]) is identified on ECG by the presence of short PR interval and delta waves. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/61/17370?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of the Wolff-Parkinson-White syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The interest for WPW in athletes is due to the concern that patients with WPW may develop arrhythmias such as atrial fibrillation, which could degenerate into ventricular fibrillation and sudden death as a result of rapid conduction over the AV accessory pathway. Exercise has been reported to be associated with an increased risk of developing AF. Therefore, sports activity may expose an athlete with ventricular preexcitation to an increased risk of sudden death.",
"   </p>",
"   <p>",
"    The European Society of Cardiology guidelines recommend that athletes with a diagnosis of ventricular preexcitation be evaluated by electrophysiologic study for the inducibility of AV reentrant tachycardia and refractoriness of the accessory pathway (shortest preexcited RR interval at rest and during exercise or adrenergic drug stimulation), as this may influence eligibility for athletic competition, risk stratification, and therapy, including catheter ablation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4184/abstract/5\">",
"     5",
"    </a>",
"    ]. Possible exceptions are athletes with intermittent loss or sudden disappearance during exercise of the WPW pattern, which suggests a long anterograde refractory period of the accessory pathway, responsible for slow ventricular response during atrial fibrillation and a low risk of sudden death. Conversely, American recommendations from the 36",
"    <sup>",
"     th",
"    </sup>",
"    Bethesda conference do not mandate electrophysiologic study for all asymptomatic WPW athletes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4184/abstract/4\">",
"     4",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    However, the Bethesda Guidelines do allow and even recommend for an invasive electrophysiologic approach for younger athletes involved in moderate to high intensity sports. A reasonable approach, in our view, is to perform electrophysiologic studies in adolescents and young adults. However, for older adults who have been self selected to survive through adolescence and young adulthood, an invasive electrophysiologic study is not mandated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H618541\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A broad range of electrocardiographic (ECG) abnormalities can be seen in trained athletes, particularly increased QRS voltage and repolarization abnormalities. In one report of 1005 athletes, distinctly abnormal ECG patterns were found in 14 percent, mildly abnormal ECG patterns in 26 percent, and a normal ECG or minor alterations in 60 percent. When the same patients were evaluated with echocardiography, only 5 percent were found to have a structural abnormality. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prevalence and etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A current approach for ECG assessment distinguishes the most common ECG abnormalities related to training, which are considered benign expressions of physiologic cardiac adaptation and do not require additional testing, from the uncommon ECG unrelated to training, which are possible expressions of underlying cardiac disease and mandate careful diagnostic investigation (",
"      <a class=\"graphic graphic_table graphicRef83350 \" href=\"UTD.htm?43/22/44395\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2027761\">",
"       'Training-related versus training-unrelated ECG changes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ECG patterns suggestive of slowed AV nodal conduction (eg, first degree AV block and Mobitz type I second degree AV block) can result from physiologic increased vagal tone in well-conditioned athletes. In the absence of symptoms, neither first degree AV block nor Mobitz type I second degree AV block requires treatment or precludes participation in athletics. However, in athletes with symptoms (eg, presyncope or syncope) possibly due to bradycardia, we recommend a noninvasive evaluation including an exercise stress test, echocardiogram, and, in some patients, 24-hour ambulatory monitoring because of the potential for underlying structural heart disease. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'First degree AV block'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Second degree AV block: Mobitz type I (Wenckebach)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mobitz type II second degree AV block and acquired complete AV block are uncommon in athletes. In the absence of a potentially reversible condition (eg, Lyme carditis), these conduction abnormalities should be treated with a pacemaker before permitting any athletic or sport activity. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Second degree AV block: Mobitz type II'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Acquired complete AV block'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Congenital complete AV block is due to an interruption of conduction between the atrium and AV node, often occurring in the absence of other structural cardiac abnormalities. Athletes with congenital heart block, a structurally normal heart and normal cardiac function, a narrow QRS complex, ventricular rates at rest &gt;40 to 50 beats per minute increasing appropriately with exertion, no history of syncope or near syncope, and no ventricular tachycardia (VT) during exertion can participate in competitive sports according to current recommendations. In contrast, athletes with congenital complete AV block and ventricular arrhythmia, symptoms of fatigue, near-syncope, or syncope should have a pacemaker implanted before they participate in competitive sports. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Congenital complete AV block'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Athletes with asymptomatic RBBB or LBBB and no ventricular arrhythmias who do not develop AV block with exercise can participate in all competitive sports consistent with their cardiac status. Periodic follow-up is suggested for all individuals with complete LBBB participating in competitive sport. There is no expert consensus or guideline recommendations regarding the frequency of follow-up, but we feel that, in the absence of symptoms, one annual follow-up with repeat ECG and echocardiography is appropriate, with additional follow-up after one year to generally be determined by the development of symptoms. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Complete right or left bundle branch block'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Athletes with pacemakers should not participate in competitive sports when the danger of bodily collision exists because such trauma may damage the pacemaker system. (See",
"      <a class=\"local\" href=\"#H174699\">",
"       'Athletes with pacemakers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A variety of conditions (eg, arrhythmogenic right ventricular cardiomyopathy, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, hypertrophic cardiomyopathy, long QT syndrome, short QT syndrome, WPW syndrome) are associated with ECG abnormalities and an increased risk of arrhythmias and SCD during or after exercise. As a general rule, nearly all patients with one of these conditions should be restricted from competitive athletics or vigorous activity. (See",
"      <a class=\"local\" href=\"#H2027821\">",
"       'Conditions with ECG abnormalities and increased risk during exercise'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H982955337\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author and UpToDate would like to thank Drs. David Bharucha and Roger Marinchak, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4184/abstract/1\">",
"      Pelliccia A, Maron BJ, Culasso F, et al. Clinical significance of abnormal electrocardiographic patterns in trained athletes. Circulation 2000; 102:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4184/abstract/2\">",
"      Serra-Grima R, Estorch M, Carri&oacute; I, et al. Marked ventricular repolarization abnormalities in highly trained athletes' electrocardiograms: clinical and prognostic implications. J Am Coll Cardiol 2000; 36:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4184/abstract/3\">",
"      Corrado D, Pelliccia A, Heidbuchel H, et al. Recommendations for interpretation of 12-lead electrocardiogram in the athlete. Eur Heart J 2010; 31:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4184/abstract/4\">",
"      Zipes DP, Ackerman MJ, Estes NA 3rd, et al. Task Force 7: arrhythmias. J Am Coll Cardiol 2005; 45:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4184/abstract/5\">",
"      Pelliccia A, Fagard R, Bj&oslash;rnstad HH, et al. Recommendations for competitive sports participation in athletes with cardiovascular disease: a consensus document from the Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Eur Heart J 2005; 26:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4184/abstract/6\">",
"      Corrado D, Basso C, Schiavon M, Thiene G. Screening for hypertrophic cardiomyopathy in young athletes. N Engl J Med 1998; 339:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4184/abstract/7\">",
"      Maron BJ, Ackerman MJ, Nishimura RA, et al. Task Force 4: HCM and other cardiomyopathies, mitral valve prolapse, myocarditis, and Marfan syndrome. J Am Coll Cardiol 2005; 45:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4184/abstract/8\">",
"      Corrado D, Basso C, Buja G, et al. Right bundle branch block, right precordial st-segment elevation, and sudden death in young people. Circulation 2001; 103:710.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 991 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.69.132.100-BE5EBB4FC7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_5_4184=[""].join("\n");
var outline_f4_5_4184=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H618541\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVALENCE AND ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2027794\">",
"      Frequency of ECG abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2027761\">",
"      Training-related versus training-unrelated ECG changes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H618639\">",
"      CONDUCTION ABNORMALITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      First degree AV block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Second degree AV block: Mobitz type I (Wenckebach)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Second degree AV block: Mobitz type II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Acquired complete AV block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Congenital complete AV block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Complete right or left bundle branch block",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2027923\">",
"      - Screening of family members in the presence of bifascicular block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H174699\">",
"      Athletes with pacemakers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2027821\">",
"      CONDITIONS WITH ECG ABNORMALITIES AND INCREASED RISK DURING EXERCISE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Arrhythmogenic right ventricular cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Brugada pattern type 1/syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25707090\">",
"      Catecholaminergic polymorphic VT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25707098\">",
"      Hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25707291\">",
"      Long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25707298\">",
"      Short QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H982954947\">",
"      WPW syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H618541\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H982955337\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/991\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/991|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/51/29489\" title=\"figure 1\">",
"      Classification exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/991|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/22/44395\" title=\"table 1\">",
"      Classification of abnormalities of the athlete electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/991|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?11/45/11989\" title=\"waveform 1\">",
"      ECG first degree AV block I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?42/35/43573\" title=\"waveform 2\">",
"      ECG Mobitz type I AV block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?28/37/29270\" title=\"waveform 3\">",
"      ECG Mobitz type II AV block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?20/42/21160\" title=\"waveform 4\">",
"      ECG third degree or complete AV block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?28/52/29509\" title=\"waveform 5\">",
"      Third degree or complete AV block with wide QRS escape",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?42/12/43210\" title=\"waveform 6\">",
"      Right bundle branch block 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?42/28/43466\" title=\"waveform 7\">",
"      Left bundle branch block 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?41/5/42078\" title=\"waveform 8\">",
"      12-lead ECG epsilon wave and T wave inversions in ARVC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?8/35/8762\" title=\"waveform 9\">",
"      ECG Brugada syndrome type I pattern",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?7/6/7271\" title=\"waveform 10\">",
"      ECG_1 Polymorphic VT in ischemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?41/58/42922\" title=\"waveform 11\">",
"      LVH tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?26/24/27008\" title=\"waveform 12\">",
"      Prolonged QT interval tutorial",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23192?source=related_link\">",
"      Arrhythmia in athletes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28250?source=related_link\">",
"      Brugada syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37641?source=related_link\">",
"      Catecholaminergic polymorphic ventricular tachycardia and other polymorphic ventricular tachycardias with a normal QT interval",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2202?source=related_link\">",
"      Clinical features of congenital long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32106?source=related_link\">",
"      Clinical manifestations and diagnosis of arrhythmogenic right ventricular cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10376?source=related_link\">",
"      Congenital third degree (complete) atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27204?source=related_link\">",
"      ECG tutorial: Chamber enlargement and hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/38/38505?source=related_link\">",
"      Early repolarization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/13/3285?source=related_link\">",
"      Electrocardiographic diagnosis of left ventricular hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/61/17370?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of the Wolff-Parkinson-White syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32007?source=related_link\">",
"      Etiology of atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41574?source=related_link\">",
"      First degree atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/62/23528?source=related_link\">",
"      Genetics and pathogenesis of arrhythmogenic right ventricular cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39784?source=related_link\">",
"      Left bundle branch block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40759?source=related_link\">",
"      Lyme carditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10344?source=related_link\">",
"      Right bundle branch block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13898?source=related_link\">",
"      Risk of sudden cardiac death in athletes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/37/31318?source=related_link\">",
"      Screening to prevent sudden cardiac death in athletes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/42/18087?source=related_link\">",
"      Second degree atrioventricular block: Mobitz type I (Wenckebach block)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/62/998?source=related_link\">",
"      Second degree atrioventricular block: Mobitz type II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/61/19417?source=related_link\">",
"      Short QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/50/3878?source=related_link\">",
"      Sinus bradycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15285?source=related_link\">",
"      Third degree (complete) atrioventricular block",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_5_4185="Overview of care for adult survivors of non-Hodgkin lymphoma";
var content_f4_5_4185=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of care for adult survivors of non-Hodgkin lymphoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/5/4185/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/5/4185/contributors\">",
"     Matthew S Davids, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/5/4185/contributors\">",
"     David C Fisher, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/5/4185/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/5/4185/contributors\">",
"     Larissa Nekhlyudov, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/5/4185/contributors\">",
"     Kenneth D Miller, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/5/4185/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/5/4185/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/5/4185/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 29, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H715790287\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-Hodgkin lymphoma (NHL) consists of a diverse group of malignant neoplasms of the lymphoid tissues variously derived from B cell progenitors, T cell progenitors, mature B cells, or mature T cells. In the United States, NHL is the fifth most common malignancy and the sixth most common cause of cancer death [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4185/abstract/1\">",
"     1",
"    </a>",
"    ]. There are a growing number of long-term survivors of NHL. This is predominantly due to an increasing incidence and improved survival after initial treatment:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 65,000 people were diagnosed with NHL in the United States in 2010, and the incidence of the disease is on the rise, doubling since the 1970s, with a continued 1 to 2 percent increase per year this century [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4185/abstract/1\">",
"       1",
"      </a>",
"      ]. These increases have been seen predominantly in high-grade, potentially curable subtypes [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4185/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      NHL is often a disease of middle-aged and older adults, a demographic that continues to increase in size as the life expectancy of the general population increases.",
"     </li>",
"     <li>",
"      Improvements in initial therapy have increased survival rates for some NHL histologies, such as diffuse large B cell lymphoma. NHL survivors now commonly live for many years after completing curative therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite improvements in treatment, NHL survivors are at risk of developing long-term complications of intensive therapy including second malignancies, cardiovascular disease, endocrine dysfunction, and cognitive sequelae.",
"   </p>",
"   <p>",
"    This topic will provide an overview to the care of the NHL survivor, focusing on issues that require attention at approximately five years from the completion of therapy onwards. Specific care of the early complications of treatment and the long-term care of the hematopoietic cell transplantation survivor are presented separately as is the subclassification of NHL. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/44/35530?source=see_link\">",
"     \"The approach to hematopoietic cell transplantation survivorship\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21337?source=see_link&amp;anchor=H8#H8\">",
"     \"Classification of the hematopoietic neoplasms\", section on 'Lymphoid neoplasms'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715790294\">",
"    <span class=\"h1\">",
"     PROGNOSIS AND NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis and natural history of NHL varies widely depending on the specific histologic subtype in addition to clinical and pathologic prognostic factors, including the general health of the patient. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=see_link&amp;anchor=H334141054#H334141054\">",
"     \"Initial evaluation and staging of non-Hodgkin lymphoma\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715790301\">",
"    <span class=\"h1\">",
"     OVERVIEW OF TREATMENT COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial treatment of NHL depends upon the histologic subtype and disease stage. Treatment options include chemotherapy, immunotherapy (eg, antibodies targeted against tumor antigens), radiation therapy, or a combination of these. A subset of patients are treated with high dose chemotherapy followed by stem cell support (ie, autologous hematopoietic cell transplantation). These therapies place NHL survivors at risk for the development of a diverse array of long-term sequelae, with the potential to negatively impact both their quality of life and ultimately their survival [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4185/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following sections describe the most common long-term complications associated with treatment. Specific details regarding the long-term complications of autologous hematopoietic cell transplantation are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/44/35530?source=see_link\">",
"     \"The approach to hematopoietic cell transplantation survivorship\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715790308\">",
"    <span class=\"h2\">",
"     Second malignancies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have shown that the risk of developing a second malignancy is increased in long term survivors of NHL [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4185/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. Risk factors depend on the type of secondary malignancy being considered, and include the use of radiation therapy, chemotherapy (eg, alkylating agents, topoisomerase II inhibitors, antimetabolites), and younger age (eg, &lt;25 years) at the time of treatment. Screening for secondary malignancies is discussed below. (See",
"    <a class=\"local\" href=\"#H20339647\">",
"     'Monitoring for complications'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39480?source=see_link&amp;anchor=H6#H6\">",
"     \"Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome\", section on 'Cytotoxic agents that have been implicated'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most studies express the risk of developing a second malignancy as a standardized incidence ratio (SIR) that reflects the ratio of observed cases to those expected in the population. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the largest study published to date, 77,876 patients with NHL reported through the NCI&rsquo;s Surveillance, Epidemiology and End Results (SEER) Program were followed, and 5638 patients developed secondary malignancies, significantly more than the endemic rate (SIR 1.14) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4185/abstract/7\">",
"       7",
"      </a>",
"      ]. Patients receiving radiotherapy as part of their NHL treatment were at particularly high risk of developing sarcomas, breast cancers, and mesothelioma. Of interest, women who did not receive radiation therapy had a decreased risk of breast cancer across all age cohorts (SIR 0.79). Similarly, the prostate cancer risk for men who had not undergone radiation therapy was also significantly lower than that expected in the standard population (SIR 0.89).",
"     </li>",
"     <li>",
"      Another large cohort study evaluated 28,131 patients diagnosed with NHL in Sweden before 2004 [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4185/abstract/9\">",
"       9",
"      </a>",
"      ]. Solid tumors developed in 2290 patients (8 percent, SIR 1.65; 95% CI 1.59-1.72) and a second lymphohematopoietic tumor developed in 369 (1 percent, SIR 5.36; 95% CI 4.84-5.94). The relative risk of developing a solid malignancy after treatment varied with the age at diagnosis and length of follow-up. Patients treated at a younger age had a higher relative risk of developing a solid malignancy. The SIR for solid tumors increased up to 30 years after NHL diagnosis, with a peak between years 21 to 30 after diagnosis.",
"     </li>",
"     <li>",
"      The risk of developing a second malignancy was studied in another cohort of 2456 patients &lt;60 years of age with NHL, who were first treated from 1973 to 2000 [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4185/abstract/10\">",
"       10",
"      </a>",
"      ]. A total of 123 second malignancies occurred (5 percent), with a 15-year cumulative risk of 11.2 percent. The most commonly seen second malignancies included lung cancer (SIR 1.6; 95% CI 1.1-2.3) and leukemia (SIR 8.8; 95% CI 5.1-14), with a trend toward an increased risk of colon cancer (SIR 1.4; 95% CI 0.7-2.6). There was a trend toward a decrease in the relative risk of breast cancer (SIR 0.7; 95% CI 0.3-1.2). The relative risk of developing a second malignancy was greater in males than females, as well as for those who were younger at the time of first treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk of developing a second malignancy likely differs depending upon the subtype of NHL and the treatment received. A retrospective analysis of the SEER registry evaluated the second cancer and leukemia risks among 43,145 patients with a history of chronic lymphocytic leukemia (CLL), diffuse large B cell lymphoma (DLBCL), or follicular lymphoma (FL) from 1992 to 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4185/abstract/11\">",
"     11",
"    </a>",
"    ]. When compared with the general population, the risk of developing lung cancer was increased among survivors of CLL (SIR 1.42) and FL (SIR 1.28), but not DLBCL (SIR 1.00). Likewise, the risk of developing cutaneous melanoma was increased after CLL (1.92) and FL (1.60), but not after DLBCL (1.06). In contrast, the risk of developing acute myeloid leukemia was increased after FL (5.96) and DLBCL (4.96), but not after CLL (1.13). These differences may be due to variation in treatments received as well as to the distinct underlying biologies of these subtypes.",
"   </p>",
"   <p>",
"    Of importance, these risks of secondary malignancy are not unique to patients with advanced stage NHL. In a small retrospective study, four patients were found to have developed squamous cell carcinoma of the head and neck after receiving radiotherapy to this area as part of definitive therapy for localized, early-stage NHL [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4185/abstract/12\">",
"     12",
"    </a>",
"    ]. This study highlights the need for close surveillance for second malignancies even for survivors of localized NHL. (See",
"    <a class=\"local\" href=\"#H20339647\">",
"     'Monitoring for complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There are few data regarding the outcomes of patients who develop a second malignancy after the treatment of NHL. Women who develop breast cancer after being cured of NHL may have a poorer prognosis than patients without prior NHL. In a study of 53 women who developed breast cancer following lymphoma, 18 (34 percent) of whom had NHL, women with a prior diagnosis of lymphoma had significantly inferior rates of five-year disease free survival (55 versus 91 percent) and overall survival (87 versus 99 percent) when compared with matched controls with de novo breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4185/abstract/13\">",
"     13",
"    </a>",
"    ]. These inferior outcomes may be related to suboptimal radiation therapy for the subsequent breast cancer among women with a prior diagnosis of lymphoma. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715790315\">",
"    <span class=\"h2\">",
"     Cardiovascular",
"    </span>",
"    &nbsp;&mdash;&nbsp;Survivors of NHL are at risk for long term cardiovascular complications related to the chemotherapy they have received (eg, anthracyclines)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiation. Chemotherapy can lead to delayed nonischemic heart failure, and chest radiation has been associated with accelerated atherosclerosis and other cardiotoxicity. Monitoring for cardiovascular disease is discussed below. Acute and chronic cardiotoxicity associated with chemotherapy agents and radiation is discussed in more detail separately. (See",
"    <a class=\"local\" href=\"#H20339647\">",
"     'Monitoring for complications'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=see_link\">",
"     \"Cardiotoxicity of anthracycline-like chemotherapy agents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40138?source=see_link\">",
"     \"Cardiotoxicity of nonanthracycline cancer chemotherapy agents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/21/34137?source=see_link\">",
"     \"Cardiotoxicity of radiation therapy for malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Initial studies likely underestimated the incidence of cardiovascular disease as a serious late adverse treatment effect among NHL survivors. For example, in a study looking at 141 survivors of both NHL and Hodgkin lymphoma, only one patient developed long term clinically significant congestive heart failure, though evidence of subclinical cardiomyopathy was detected on echocardiogram in 39 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4185/abstract/14\">",
"     14",
"    </a>",
"    ]. Subsequent studies suggest that the long term clinically significant cardiovascular risks of undergoing chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiotherapy for NHL may be more substantial than was previously appreciated.",
"   </p>",
"   <p>",
"    A Dutch-Belgian study calculated the risks of development of cardiovascular disease in 476 patients with aggressive NHL treated with at least six cycles of doxorubicin-containing chemotherapy in the 1980s and 1990s [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4185/abstract/15\">",
"     15",
"    </a>",
"    ]. Relative risk was expressed as a standard incidence ratio (SIR) calculated as the observed incidence divided by the expected incidence. At a median follow-up of 8.4 years, the five- and 10-year cumulative incidences of cardiovascular disease were 12 and 22 percent, respectively. The following relative risks were observed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risk of chronic heart failure (CHF) was markedly increased (SIR 5.4; 95% CI 4.1-6.9). Most of the cases of CHF observed were found to be due to non-ischemic cardiomyopathy, with rhythm disturbances identified much more frequently than coronary artery disease.",
"     </li>",
"     <li>",
"      The risk of coronary artery disease matched that of the general population (SIR 1.2; 95% CI 0.8-1.8) and appeared more related to age than to treatment.",
"     </li>",
"     <li>",
"      The risk of stroke was increased (SIR 1.8; 95% CI 1.1-2.4), especially after radiation therapy in doses &gt;40 Gy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This study also identified key risk factors for the development of cardiovascular events in NHL survivors. Preexisting hypertension, young age at NHL diagnosis, need for salvage treatment, and amount of radiotherapy all correlated with an increased risk of the subsequent development of cardiac disease. Those patients receiving lower amounts of radiation (&lt;40 Gy) and those not receiving mediastinal radiation appeared to be at the lowest risk of future cardiotoxicity. (See",
"    <a class=\"local\" href=\"#H20339647\">",
"     'Monitoring for complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715790322\">",
"    <span class=\"h2\">",
"     Infertility and endocrine dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;NHL survivors are at risk for developing endocrine abnormalities such as gonadal dysfunction and hypothyroidism. Screening for endocrine dysfunction is discussed below. (See",
"    <a class=\"local\" href=\"#H20339647\">",
"     'Monitoring for complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H357662\">",
"    <span class=\"h3\">",
"     Gonadal dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytotoxic agents and radiation therapy can produce gonadal dysfunction in both male and female survivors of NHL. NHL is generally diagnosed in middle or older aged individuals who have completed their childbearing. As such, the effects of treatment on fertility are not problematic for many survivors. However, for younger patients treated for NHL, decreased fertility following treatment is a major concern. This risk increases the older a patient is at the time of treatment. Patients at the highest risk for infertility are those who received multiple chemotherapy regimens and those treated with high dose chemotherapy followed by hematopoietic cell transplantation (HCT). A more detailed discussion of reproductive and sexual issues in HCT survivors and an overview of fertility and pregnancy in cancer survivors, in general, are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7977?source=see_link\">",
"     \"Overview of fertility and pregnancy in cancer survivors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/26/1447?source=see_link&amp;anchor=H7#H7\">",
"     \"Ovarian failure due to anticancer drugs and radiation\", section on 'Ovarian suppression'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38010?source=see_link\">",
"     \"Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to patients who have received multiple chemotherapy regimens for relapsed or refractory NHL, patients cured after initial chemotherapy for NHL can generally be reassured that their risk for infertility is low. A study of 36 Israeli women treated for clinically aggressive subtypes of NHL found that, although half of the patients had amenorrhea during treatment, all but two patients recovered menses in first remission, typically in the first three months after completing chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4185/abstract/16\">",
"     16",
"    </a>",
"    ]. Eighteen patients (50 percent) became pregnant while in first remission. Medical fertility-preserving measures (ie, contraceptive pills, gonadotropin-releasing hormone analogs) were not associated with improvements in recovery of regular menstruation or increased rates of pregnancy.",
"   </p>",
"   <p>",
"    Another study looked at the effects of an intensified chemotherapy regimen with high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (Mega-CHOP) in 13 consecutive younger women (&lt;40 years) with clinically aggressive subtypes of NHL [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4185/abstract/17\">",
"     17",
"    </a>",
"    ]. Similarly, they found no significant effect of this regimen on fertility, with only one case of premature ovarian failure. Eight patients conceived spontaneously and delivered healthy babies.",
"   </p>",
"   <p>",
"    Male NHL survivors may also be concerned about the effects of chemotherapy and radiation on their fertility. A study from Norway of approximately 300 men under the age of 50 who were survivors of either NHL or Hodgkin lymphoma were treated with a variety of chemotherapy regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4185/abstract/18\">",
"     18",
"    </a>",
"    ]. Patients with NHL treated with CHOP-based chemotherapy were not at significantly increased risk of endocrine hypogonadism, as determined by LH, FSH, and testosterone levels. Approximately 20 percent of these patients did have abnormal hormonal levels, but this was not significantly different than a group of patients receiving either no chemotherapy or receiving ABVD chemotherapy for Hodgkin lymphoma (which is not typically associated with infertility). Endocrine hypogonadism was more common in men over age 50 years and in patients with NHL requiring more intensive regimens such as autologous hematopoietic cell transplantation. Spermatic function and fertility were not specifically assessed in this study.",
"   </p>",
"   <p>",
"    NHL survivors should be referred to a physician with expertise in reproductive endocrinology as needed for the evaluation and management of infertility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H357655\">",
"    <span class=\"h3\">",
"     Other endocrinopathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Less is known about other endocrinopathies resulting from treatment of NHL. Radiation to the neck and mediastinum can lead to hypothyroidism, and a small subgroup of NHL patients undergoing hematopoietic cell transplantation with total body irradiation (TBI) conditioning were reported to suffer from growth hormone deficiency, hypogonadism, insulin resistance, and dyslipidemia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4185/abstract/19\">",
"     19",
"    </a>",
"    ]. The incidence of these endocrine abnormalities in NHL survivors after initial therapy alone is not well-described. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/44/35530?source=see_link&amp;anchor=H94492389#H94492389\">",
"     \"The approach to hematopoietic cell transplantation survivorship\", section on 'Endocrine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    NHL survivors whose treatment included radiation to the neck or mediastinum should have an assay of thyroid stimulating hormone (TSH) measured one year after the completion of therapy and then annually. If the serum TSH concentration is elevated, the TSH measurement should be repeated along with a serum free T4 to make the diagnosis of hypothyroidism. Assays can be performed earlier if clinical suspicion exists, but the clinician must be aware of the possibility of acquired transient central hypothyroidism (the sick-euthyroid syndrome) early after radiation treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=see_link\">",
"     \"Diagnosis of and screening for hypothyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44663?source=see_link\">",
"     \"Thyroid function in nonthyroidal illness\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715790329\">",
"    <span class=\"h2\">",
"     Neurologic and psychiatric complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurologic complications due to treatment of NHL are rare but potentially serious. Risk factors for neurocognitive impairment include central nervous system involvement, cranial irradiation, a history of intrathecal chemotherapy, older age at the time of treatment, and hematopoietic cell transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4185/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Patients treated with the anti-CD20 monoclonal antibody",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    are at risk for the development of progressive multifocal leukoencephalopathy (PML). NHL survivors are also at risk for psychiatric complications following the completion of treatment, including posttraumatic stress disorder (PTSD) and depression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=see_link\">",
"     \"Complications of cranial irradiation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26681?source=see_link\">",
"     \"Progressive multifocal leukoencephalopathy: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27352?source=see_link\">",
"     \"Posttraumatic stress disorder: Epidemiology, pathophysiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following studies addressed neurologic complications in NHL survivors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective study of 52 patients with lymphoproliferative disorders who developed PML following",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      -based therapies reported that this condition typically develops soon after completing therapy, with a median time from last rituximab dose to PML diagnosis of 5.5 months [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4185/abstract/22\">",
"       22",
"      </a>",
"      ]. Although still a very rare complication of rituximab use, the lethality of this condition is high, with a 90 percent case-fatality rate and a median time to death of only two months after PML diagnosis. No clear risk factors for the development of PML have been identified.",
"     </li>",
"     <li>",
"      In a study of 28 patients with primary CNS lymphoma who had completed treatment with whole brain radiotherapy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      high-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      , mild to moderate impairments were found in multiple cognitive domains [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4185/abstract/20\">",
"       20",
"      </a>",
"      ]. Deficits in memory, attention, and executive domains were particularly prominent. Patient who underwent whole brain radiation therapy had more pronounced deficits than those who had chemotherapy alone. In a subsequent prospective study, a similar group of patients were found to have some recovery of executive domain function at two years, but they continued to have persistent difficulties with verbal memory and motor speed [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4185/abstract/23\">",
"       23",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37914?source=see_link&amp;anchor=H5#H5\">",
"       \"Treatment and prognosis of primary central nervous system lymphoma\", section on 'Is there a role for radiation therapy?'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In a survey of 886 NHL survivors who were on average 10 years post-diagnosis, 39 percent reported symptoms of PTSD, and 8 percent met diagnostic criteria for PTSD [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4185/abstract/24\">",
"       24",
"      </a>",
"      ]. Younger, non-Caucasian patients with less education were more likely to experience these symptoms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All patients at increased risk should undergo screening for neurocognitive impairment so that appropriate occupational therapy and social services referrals may be made, if necessary. Oncologists and primary care physicians should be aware of the high prevalence of mental health issues faced by NHL survivors. As an example, the early identification of patients with symptoms of posttraumatic stress disorder can facilitate referral to mental health professionals to initiate treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4185/abstract/24\">",
"     24",
"    </a>",
"    ]. Such interventions can aid greatly in patients&rsquo; ability to return as closely as possible to the quality of life they enjoyed before their NHL diagnosis and treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/6/32873?source=see_link&amp;anchor=H418032811#H418032811\">",
"     \"Overview of cancer survivorship care for primary care and oncology providers\", section on 'Psychosocial well being'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715790343\">",
"    <span class=\"h1\">",
"     POSTTREATMENT SURVEILLANCE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20339640\">",
"    <span class=\"h2\">",
"     Monitoring for relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following the completion of therapy, restaging, and documentation of complete remission, patients are seen at periodic intervals to be monitored and assessed for possible relapse. The frequency and extent of these visits depends upon the histologic subtype and comfort of both the patient and physician. There have been no prospective, randomized trials comparing various schedules of follow-up. Our approach to monitoring for recurrent disease is discussed separately for the individual NHL histologies. Relapsed disease can be suggested by changes on imaging studies but can only be confirmed by biopsy. As such, a biopsy should be obtained to document relapsed disease before proceeding to salvage therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=see_link&amp;anchor=H28#H28\">",
"     \"Initial treatment of advanced stage diffuse large B cell lymphoma\", section on 'Surveillance for relapse'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9865?source=see_link&amp;anchor=H25#H25\">",
"     \"Initial treatment of limited stage (I/II) follicular lymphoma\", section on 'Surveillance for relapse'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33065?source=see_link&amp;anchor=H22#H22\">",
"     \"Initial treatment of peripheral T cell lymphoma\", section on 'Surveillance for relapse'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/23/36217?source=see_link&amp;anchor=H17#H17\">",
"     \"Treatment of Burkitt leukemia/lymphoma in adults\", section on 'Surveillance for relapse'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/17/18714?source=see_link&amp;anchor=H19677745#H19677745\">",
"     \"Initial treatment of advanced stage (III/IV) follicular lymphoma\", section on 'Surveillance for relapse'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Relapse is much less likely to occur greater than five years after the completion of treatment. From this point forward, it is even less clear how intensively patients need to be followed. A growing trend has been for patients to transition back to their primary care physician, who often oversees this portion of the care. Given the increasing prevalence of NHL, it is therefore imperative that internists be aware of the potential late complications of NHL treatment. (See",
"    <a class=\"local\" href=\"#H715790357\">",
"     'Coordination of care'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20339647\">",
"    <span class=\"h2\">",
"     Monitoring for complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;No uniform guidelines exist for how to monitor NHL survivors for long term complications. Our approach is based upon our experience and extrapolation of data from patients with other primary malignancies (",
"    <a class=\"graphic graphic_table graphicRef71708 \" href=\"UTD.htm?0/49/797\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Cancer screening",
"      </strong>",
"      &mdash; While NHL survivors are at increased risk of developing secondary malignancies, the ideal screening program has not been defined. No prospective analyses have evaluated the benefit of screening in this population. However, extrapolation of data from other settings suggests that the ability to prevent and detect solid organ malignancies in the NHL survivor relies upon periodic screening examinations and strict adherence to prophylactic measures:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Risk awareness counseling annually &mdash; NHL survivors should be advised of their increased risk of developing a malignancy following treatment and encouraged to report any concerning symptoms to their physician. Smoking cessation should be recommended, and patients should be counseled to limit unprotected sun exposure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=see_link\">",
"       \"Overview of smoking cessation management in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Screening clinical assessment annually &mdash; In addition to a routine physical examination, NHL survivors should undergo an at least annual complete skin examination to monitor for the development of skin cancers. &nbsp;",
"     </li>",
"     <li>",
"      NHL survivors should be encouraged to participate in routine age-appropriate cancer surveillance with the following notable exceptions (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37962?source=see_link&amp;anchor=H9#H9\">",
"       \"Overview of preventive medicine in adults\", section on 'Cancer morbidity and mortality'",
"      </a>",
"      ):",
"     </li>",
"     <li>",
"      Female NHL survivors should undergo screening for breast cancer beginning no later than age 40 years. For patients who have received total body or chest irradiation, breast cancer screening should begin eight years after radiation or at age 25 years, whichever occurs later. The ideal test to use for breast cancer screening has not been determined and clinical practice varies. The American Cancer Society suggests the use of mammography to screen most women for breast cancers, but also proposes that woman who received radiation to the chest between the age of 10 and 35 years undergo screening with both annual breast magnetic resonance imaging (MRI) and mammography [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4185/abstract/25,26\">",
"       25,26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other studies &mdash; There are little data to support additional screening measures such as periodic complete blood counts to screen for leukemia or myelodysplastic syndrome, chest radiographs to screen for lung cancer or mesothelioma, or an increase in the frequency of colonoscopy to screen for colorectal cancer.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Cardiovascular health",
"      </strong>",
"      &mdash; Screening and counseling techniques similar to those used for other high risk populations are applied to NHL survivors with the goal of decreasing mortality from cardiovascular disease. Cardiac risk factors should be minimized (eg, smoking, obesity, hyperlipidemia, hypertension). Routine care should incorporate regular measurement and control of blood pressure, auscultation of the carotids for bruits, nutritional counseling and obesity control, counseling for smoking cessation, and control of diabetes. In addition, we commonly refer NHL survivors to a cardiologist for baseline evaluation after the completion of treatment and determination of the necessity and frequency of additional screening or diagnostic studies (eg, resting and stress echocardiogram). Cardiac evaluation is especially important for patients who have received radiation therapy, particularly once 10 years have passed since the radiation therapy. At a minimum, patients should be instructed not to ignore persistent troubling symptoms and to bring them to the attention of their physician without delay. Physicians must be aware of NHL survivors&rsquo; treatment history; additional testing should be pursued if suspicion of a late complication arises. (See",
"      <a class=\"local\" href=\"#H715790315\">",
"       'Cardiovascular'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Endocrine assessment",
"      </strong>",
"      &mdash; NHL survivors whose treatment included radiation to the neck or mediastinum should have an assay of thyroid stimulating hormone (TSH) measured one year after the completion of therapy and then annually. If the serum TSH concentration is elevated, the TSH measurement should be repeated along with a serum free T4 to make the diagnosis of hypothyroidism. (See",
"      <a class=\"local\" href=\"#H715790322\">",
"       'Infertility and endocrine dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Neurologic and psychiatric evaluation",
"      </strong>",
"      &mdash; Annual evaluation should include a discussion of psychiatric health including an assessment of symptoms of depression and posttraumatic stress disorder. All patients at increased risk (eg, history of cranial irradiation, intrathecal therapy) should undergo screening for neurocognitive impairment so that appropriate occupational therapy and social services referrals may be made, if necessary. (See",
"      <a class=\"local\" href=\"#H715790329\">",
"       'Neurologic and psychiatric complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715790350\">",
"    <span class=\"h2\">",
"     Lifestyle modifications",
"    </span>",
"    &nbsp;&mdash;&nbsp;At each visit, NHL survivors should be encouraged to incorporate healthy practices into their lifestyle in order to decrease the risk of developing complications.",
"   </p>",
"   <p>",
"    The cardiovascular sequelae of NHL treatment can be mitigated through active lifestyle modifications. Reducing or eliminating comorbid conditions, such as diabetes, hypertension, hyperlipidemia, and obesity, is important. Smokers should be encouraged to quit, both to reduce the risk of cardiac disease and of lung cancer. Resources should be provided to NHL survivors who smoke to educate them about the behavioral and pharmacologic interventions that can assist with smoking cessation efforts. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=see_link\">",
"     \"Overview of smoking cessation management in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Engaging in regular physical activity appears to be particularly critical in helping NHL survivors to be healthy. As an example, two studies demonstrated that those NHL survivors who met the public health guidelines of 150 minutes or more of moderately vigorous exercise per week had significantly better health-related quality of life than those who were sedentary [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4185/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Health-related quality of life was also found to have a positive correlation with getting at least some exercise. Therefore, all NHL survivors should be encouraged to participate in at least some exercise, with patients informed that the more exercise they get, the better chance they have of improving their quality of life. Consultation with exercise physiologists and nutritionists may be appropriate in select patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715790357\">",
"    <span class=\"h1\">",
"     COORDINATION OF CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;During treatment, NHL patients become accustomed to working closely with a multidisciplinary team that often includes medical oncologists, radiation oncologists, mid-level practitioners, nurses, and others. Ideally, involvement of the patient&rsquo;s primary care physician (PCP) continues during treatment, as the PCP often has a long-standing relationship with the patient that pre-dates the patient&rsquo;s lymphoma diagnosis. Maintaining this relationship becomes particularly important after the patient completes treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/6/32873?source=see_link&amp;anchor=H418030689#H418030689\">",
"     \"Overview of cancer survivorship care for primary care and oncology providers\", section on 'Coordination of care'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Typically, the medical oncologist follows the patient closely for several years after finishing therapy, and subsequently the patient transitions back to the PCP as his or her main provider. This transition period can be fraught with miscommunication between even the most well-meaning providers. Establishing a survivorship care plan is one way to facilitate communication and allocation of responsibility during this time period [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4185/abstract/29\">",
"     29",
"    </a>",
"    ]. The patient&rsquo;s attendance of a survivorship clinic, where available, can also aid in promoting well-coordinated care.",
"   </p>",
"   <p>",
"    Through a deepened understanding of late treatment effects, we can begin to more effectively counsel our patients on the risks they face and the lifestyle modifications and other interventions that can reduce the ill effects of these complications. Effectively managing these consequences of therapy may improve the quality of life of NHL survivors and has the potential to prolong their survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/23/18802?source=see_link\">",
"       \"Patient information: Follicular lymphoma (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/19/26930?source=see_link\">",
"       \"Patient information: Diffuse large B-cell lymphoma (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?8/9/8339?source=see_link\">",
"       \"Patient information: Follicular lymphoma in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?26/60/27588?source=see_link\">",
"       \"Patient information: Diffuse large B-cell lymphoma in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715790371\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are a growing number of long-term survivors of non-Hodgkin lymphoma (NHL). These patients must be monitored periodically not only for disease recurrence, but also for long term complications related to the disease and its treatment. No uniform guidelines exist for how to monitor NHL survivors for long term complications. Our approach is based upon our experience and extrapolation of data from patients with other primary malignancies (",
"      <a class=\"graphic graphic_table graphicRef71708 \" href=\"UTD.htm?0/49/797\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20339647\">",
"       'Monitoring for complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk of developing both hematologic and solid tumor second malignancies is increased in long term survivors of NHL, and likely differs depending upon the subtype of NHL and the treatment received. This risk is cumulative and continues for at least 30 years after completing treatment. While patients with advanced stage at the time of diagnosis are at highest risk, even those with localized disease, particularly those treated with radiotherapy at a young age, also have elevated risk. (See",
"      <a class=\"local\" href=\"#H715790308\">",
"       'Second malignancies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Survivors of NHL are at risk for long term cardiovascular complications (eg, congestive heart failure, stroke) related to the chemotherapy they have received (eg, anthracyclines)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      radiation. Risk factors include preexisting hypertension, young age at NHL diagnosis, need for second-line treatment, and the amount of radiotherapy received. Initial subclinical cardiac sequelae can put NHL survivors at risk for more serious cardiac events. (See",
"      <a class=\"local\" href=\"#H715790315\">",
"       'Cardiovascular'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cytotoxic agents and radiation therapy can produce gonadal dysfunction in both male and female survivors of NHL. Infertility is relatively uncommon among younger patients who achieved remission following initial therapy. Infertility rates are higher among older patients and those receiving high dose chemotherapy followed by autologous hematopoietic cell transplantation, as well as those receiving second line chemotherapy. Survivors who received neck",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      mediastinal radiation are at risk for developing hypothyroidism. (See",
"      <a class=\"local\" href=\"#H715790322\">",
"       'Infertility and endocrine dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      NHL survivors are at risk of developing neurologic (eg, neurocognitive impairment) and psychiatric (posttraumatic stress disorder) complications. Risk factors for neurocognitive impairment include central nervous system involvement, cranial irradiation, intrathecal chemotherapy, older age at the time of treatment, and hematopoietic cell transplantation. Progressive multifocal leukoencephalopathy is a rare but generally fatal toxicity associated with the anti-CD20 monoclonal antibody",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H715790329\">",
"       'Neurologic and psychiatric complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lifestyle modification, including regular exercise, smoking cessation, and a healthy diet are all important in minimizing the severity of late treatment sequelae. (See",
"      <a class=\"local\" href=\"#H715790350\">",
"       'Lifestyle modifications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Coordination of care among the medical oncologist, primary care physician, and other healthcare professionals is critical and can be facilitated by the patient&rsquo;s participation in a survivorship clinic, where available. (See",
"      <a class=\"local\" href=\"#H715790357\">",
"       'Coordination of care'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     SEER Database file://seer.cancer.gov/ (Accessed on March 18, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4185/abstract/2\">",
"      M&uuml;ller AM, Ihorst G, Mertelsmann R, Engelhardt M. Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology. Ann Hematol 2005; 84:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4185/abstract/3\">",
"      Blaes AH, Ma L, Zhang Y, Peterson BA. Quality of life appears similar between survivors of indolent and aggressive non-Hodgkin lymphoma. Leuk Lymphoma 2011; 52:2105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4185/abstract/4\">",
"      Smith SK, Zimmerman S, Williams CS, Zebrack BJ. Health status and quality of life among non-Hodgkin lymphoma survivors. Cancer 2009; 115:3312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4185/abstract/5\">",
"      Oerlemans S, Mols F, Nijziel MR, et al. The impact of treatment, socio-demographic and clinical characteristics on health-related quality of life among Hodgkin's and non-Hodgkin's lymphoma survivors: a systematic review. Ann Hematol 2011; 90:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4185/abstract/6\">",
"      Travis LB, Curtis RE, Glimelius B, et al. Second cancers among long-term survivors of non-Hodgkin's lymphoma. J Natl Cancer Inst 1993; 85:1932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4185/abstract/7\">",
"      Tward JD, Wendland MM, Shrieve DC, et al. The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer 2006; 107:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4185/abstract/8\">",
"      Pirani M, Marcheselli R, Marcheselli L, et al. Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis. Ann Oncol 2011; 22:1845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4185/abstract/9\">",
"      Hemminki K, Lenner P, Sundquist J, Bermejo JL. Risk of subsequent solid tumors after non-Hodgkin's lymphoma: effect of diagnostic age and time since diagnosis. J Clin Oncol 2008; 26:1850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4185/abstract/10\">",
"      Mudie NY, Swerdlow AJ, Higgins CD, et al. Risk of second malignancy after non-Hodgkin's lymphoma: a British Cohort Study. J Clin Oncol 2006; 24:1568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4185/abstract/11\">",
"      Morton LM, Curtis RE, Linet MS, et al. Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype. J Clin Oncol 2010; 28:4935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4185/abstract/12\">",
"      Toda K, Shibuya H, Hayashi K, Ayukawa F. Radiation-induced cancer after radiotherapy for non-Hodgkin's lymphoma of the head and neck: a retrospective study. Radiat Oncol 2009; 4:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4185/abstract/13\">",
"      Sanna G, Lorizzo K, Rotmensz N, et al. Breast cancer in Hodgkin's disease and non-Hodgkin's lymphoma survivors. Ann Oncol 2007; 18:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4185/abstract/14\">",
"      Hequet O, Le QH, Moullet I, et al. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol 2004; 22:1864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4185/abstract/15\">",
"      Moser EC, Noordijk EM, van Leeuwen FE, et al. Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma. Blood 2006; 107:2912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4185/abstract/16\">",
"      Elis A, Tevet A, Yerushalmi R, et al. Fertility status among women treated for aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 2006; 47:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4185/abstract/17\">",
"      Dann EJ, Epelbaum R, Avivi I, et al. Fertility and ovarian function are preserved in women treated with an intensified regimen of cyclophosphamide, adriamycin, vincristine and prednisone (Mega-CHOP) for non-Hodgkin lymphoma. Hum Reprod 2005; 20:2247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4185/abstract/18\">",
"      Kiserud CE, Foss&aring; A, Bj&oslash;ro T, et al. Gonadal function in male patients after treatment for malignant lymphomas, with emphasis on chemotherapy. Br J Cancer 2009; 100:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4185/abstract/19\">",
"      Steffens M, Beauloye V, Brichard B, et al. Endocrine and metabolic disorders in young adult survivors of childhood acute lymphoblastic leukaemia (ALL) or non-Hodgkin lymphoma (NHL). Clin Endocrinol (Oxf) 2008; 69:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4185/abstract/20\">",
"      Correa DD, DeAngelis LM, Shi W, et al. Cognitive functions in survivors of primary central nervous system lymphoma. Neurology 2004; 62:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4185/abstract/21\">",
"      Rizzo JD, Wingard JR, Tichelli A, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2006; 12:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4185/abstract/22\">",
"      Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113:4834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4185/abstract/23\">",
"      Correa DD, Rocco-Donovan M, DeAngelis LM, et al. Prospective cognitive follow-up in primary CNS lymphoma patients treated with chemotherapy and reduced-dose radiotherapy. J Neurooncol 2009; 91:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4185/abstract/24\">",
"      Smith SK, Zimmerman S, Williams CS, et al. Post-traumatic stress outcomes in non-Hodgkin's lymphoma survivors. J Clin Oncol 2008; 26:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4185/abstract/25\">",
"      Kriege M, Brekelmans CT, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004; 351:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4185/abstract/26\">",
"      Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007; 57:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4185/abstract/27\">",
"      Bellizzi KM, Rowland JH, Arora NK, et al. Physical activity and quality of life in adult survivors of non-Hodgkin's lymphoma. J Clin Oncol 2009; 27:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4185/abstract/28\">",
"      Vallance JK, Courneya KS, Jones LW, Reiman T. Differences in quality of life between non-Hodgkin's lymphoma survivors meeting and not meeting public health exercise guidelines. Psychooncology 2005; 14:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4185/abstract/29\">",
"      Grunfeld E, Earle CC. The interface between primary and oncology specialty care: treatment through survivorship. J Natl Cancer Inst Monogr 2010; 2010:25.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16199 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-D40D2B0C78-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_5_4185=[""].join("\n");
var outline_f4_5_4185=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H715790371\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H715790287\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H715790294\">",
"      PROGNOSIS AND NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H715790301\">",
"      OVERVIEW OF TREATMENT COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H715790308\">",
"      Second malignancies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H715790315\">",
"      Cardiovascular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H715790322\">",
"      Infertility and endocrine dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H357662\">",
"      - Gonadal dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H357655\">",
"      - Other endocrinopathies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H715790329\">",
"      Neurologic and psychiatric complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H715790343\">",
"      POSTTREATMENT SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20339640\">",
"      Monitoring for relapse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20339647\">",
"      Monitoring for complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H715790350\">",
"      Lifestyle modifications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H715790357\">",
"      COORDINATION OF CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H715790371\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/16199\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/16199|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/49/797\" title=\"table 1\">",
"      Monitoring the NHL survivor for long-term complications",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=related_link\">",
"      Cardiotoxicity of anthracycline-like chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40138?source=related_link\">",
"      Cardiotoxicity of nonanthracycline cancer chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/21/34137?source=related_link\">",
"      Cardiotoxicity of radiation therapy for malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21337?source=related_link\">",
"      Classification of the hematopoietic neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=related_link\">",
"      Complications of cranial irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=related_link\">",
"      Diagnosis of and screening for hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38010?source=related_link\">",
"      Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=related_link\">",
"      Initial evaluation and staging of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/17/18714?source=related_link\">",
"      Initial treatment of advanced stage (III/IV) follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=related_link\">",
"      Initial treatment of advanced stage diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9865?source=related_link\">",
"      Initial treatment of limited stage (I/II) follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33065?source=related_link\">",
"      Initial treatment of peripheral T cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/26/1447?source=related_link\">",
"      Ovarian failure due to anticancer drugs and radiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/6/32873?source=related_link\">",
"      Overview of cancer survivorship care for primary care and oncology providers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7977?source=related_link\">",
"      Overview of fertility and pregnancy in cancer survivors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37962?source=related_link\">",
"      Overview of preventive medicine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=related_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/19/26930?source=related_link\">",
"      Patient information: Diffuse large B-cell lymphoma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/60/27588?source=related_link\">",
"      Patient information: Diffuse large B-cell lymphoma in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/23/18802?source=related_link\">",
"      Patient information: Follicular lymphoma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/9/8339?source=related_link\">",
"      Patient information: Follicular lymphoma in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27352?source=related_link\">",
"      Posttraumatic stress disorder: Epidemiology, pathophysiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26681?source=related_link\">",
"      Progressive multifocal leukoencephalopathy: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/44/35530?source=related_link\">",
"      The approach to hematopoietic cell transplantation survivorship",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39480?source=related_link\">",
"      Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44663?source=related_link\">",
"      Thyroid function in nonthyroidal illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37914?source=related_link\">",
"      Treatment and prognosis of primary central nervous system lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/23/36217?source=related_link\">",
"      Treatment of Burkitt leukemia/lymphoma in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_5_4186="Management of anastomotic complications of colorectal surgery";
var content_f4_5_4186=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of anastomotic complications of colorectal surgery",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/5/4186/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/5/4186/contributors\">",
"     Robin Boushey, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/5/4186/contributors\">",
"     Lara J Williams, MD, MSc, FRCSC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/5/4186/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/5/4186/contributors\">",
"     Martin Weiser, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/5/4186/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/5/4186/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/5/4186/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H800314\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The safety of colorectal surgery, as performed in patients with colorectal cancer and inflammatory bowel disease, has improved dramatically over the last 50 years due to improvements in preoperative preparation, antibiotic prophylaxis, surgical technique, and postoperative management [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/1\">",
"     1",
"    </a>",
"    ]. Nevertheless, complications continue to occur. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/49/30489?source=see_link\">",
"     \"Overview of the management of primary colon cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38137?source=see_link\">",
"     \"Overview of surgical procedures for resectable primary rectal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4906?source=see_link\">",
"     \"Surgical management of ulcerative colitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risks, management, and outcomes of anastomotic complications of colorectal surgery will be reviewed here. These complications include bleeding, dehiscence and leakage, strictures, and fistulas [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/2\">",
"     2",
"    </a>",
"    ]. The risks, management, and outcomes of intra-abdominal, pelvic, and genitourinary complications following colorectal surgery are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/57/1946?source=see_link\">",
"     \"Management of intra-abdominal, pelvic, and genitourinary complications of colorectal surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H800321\">",
"    <span class=\"h1\">",
"     MORBIDITY AND MORTALITY RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colorectal surgery is associated with appreciable morbidity and mortality. A number of prospective studies, both multicenter and single center, have evaluated patient outcomes after colorectal surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/3-9\">",
"     3-9",
"    </a>",
"    ]. The rate of major morbidity ranged from 20 to 35 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/4,7\">",
"     4,7",
"    </a>",
"    ] and the 30-day mortality rate ranged from 2 to 9 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/4-9\">",
"     4-9",
"    </a>",
"    ]. There does not appear to be a significant difference in 30-day mortality rate between malignant versus benign indications for surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/4,7,9\">",
"     4,7,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Independent preoperative risk factors that are associated with an increased risk of in-hospital complications include [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/4,7\">",
"     4,7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age greater than 70 years",
"     </li>",
"     <li>",
"      American Society of Anesthesiologists (ASA) physical status score - Grade III to V",
"     </li>",
"     <li>",
"      Emergency surgery",
"     </li>",
"     <li>",
"      Neurologic comorbidity",
"     </li>",
"     <li>",
"      Cardiorespiratory comorbidity",
"     </li>",
"     <li>",
"      Hypoalbuminemia",
"     </li>",
"     <li>",
"      Long duration of operative procedure",
"     </li>",
"     <li>",
"      Peritoneal contamination",
"     </li>",
"     <li>",
"      Rectal excision",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Independent preoperative risk factors that are associated with an increased risk of in-hospital and 30-day mortality include [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/4-9\">",
"     4-9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Emergency surgery",
"     </li>",
"     <li>",
"      Loss of greater than 10 percent total body weight",
"     </li>",
"     <li>",
"      Neurologic comorbidity",
"     </li>",
"     <li>",
"      Age greater than 70 years",
"     </li>",
"     <li>",
"      Stage IV cancer (versus earlier stage cancer)",
"     </li>",
"     <li>",
"      ASA physical status score - Grade III to V",
"     </li>",
"     <li>",
"      Low surgeon case volume",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H800328\">",
"    <span class=\"h1\">",
"     ANASTOMOTIC COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intestinal anastomotic complications are associated with an increased patient mortality and morbidity, including the potential need for emergent reoperation and prolonged hospitalization. The most common complications include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Minor and major bleeding",
"     </li>",
"     <li>",
"      Dehiscence and leaks",
"     </li>",
"     <li>",
"      Strictures",
"     </li>",
"     <li>",
"      Fistulas",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18827910\">",
"    <span class=\"h2\">",
"     Minor bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Minor bleeding is defined as bleeding that does not require blood transfusion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intervention (endoscopic, angiographic, or surgical) and that usually ceases within 24 hours. Minor anastomotic bleeding after hand-sewn and stapled anastomoses is common but rarely reported, and is usually manifested by the self-limited passage of dark blood with the patient's first few bowel movements. It is estimated that approximately 50 percent of patients who present initially with minor bleeding will progress to major bleeding and require a blood transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/10\">",
"     10",
"    </a>",
"    ]. There are no high quality data from prospective studies that have addressed this issue.",
"   </p>",
"   <p>",
"    It is hypothesized that anastomotic bleeding occurs secondary to inadequate clearance of the mesentery prior to division",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    stapling of the bowel. The risk of bleeding is increased in patients with a bleeding diathesis. Proposed techniques to reduce minor bleeding include [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Careful inspection of the staple line, especially for side to side and functional end to end anastomoses",
"     </li>",
"     <li>",
"      Inversion and inspection of the linear staple line prior to closure of the enterotomy through which a stapling instrument was passed",
"     </li>",
"     <li>",
"      Suture ligation, as opposed to electrocauterization of bleeding points",
"     </li>",
"     <li>",
"      Utilization of the antimesenteric borders of each limb to construct the anastomosis, thereby avoiding inclusion of the mesentery into the staple line",
"     </li>",
"     <li>",
"      Reinforcement of the anastomosis with an absorbable suture is an option used by some surgeons",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H800342\">",
"    <span class=\"h2\">",
"     Major bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major bleeding is defined as one or more of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hemodynamic instability",
"     </li>",
"     <li>",
"      Blood transfusion",
"     </li>",
"     <li>",
"      An emergency procedure is warranted (eg, endoscopic, angiographic, surgical).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The reported rate of major bleeding from an anastomosis following colorectal surgery ranges in most studies from 0.5 to 4.2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/10,12-14\">",
"     10,12-14",
"    </a>",
"    ]. Data are limited for ileocolic anastomoses [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/2\">",
"     2",
"    </a>",
"    ].There is no significant association between the risk of bleeding and the technique of performing the anastomosis (hand-sewn versus stapled colocolic anastomoses) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/14\">",
"     14",
"    </a>",
"    ]. Specific risk factors for major anastomotic bleeding have not been identified, at least in part due to the small number of reported cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H800349\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of patients with anastomotic bleeding should follow the same principles as the management of patients with lower gastrointestinal bleeding from other causes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30841?source=see_link\">",
"     \"Approach to resuscitation and diagnosis of acute lower gastrointestinal bleeding in the adult patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29513?source=see_link\">",
"     \"Diagnostic approach to lower gastrointestinal bleeding in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgical intervention should be reserved for unstable patients or those who fail conservative measures [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/13\">",
"     13",
"    </a>",
"    ]. We suggest the following approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initial management should be conservative with supportive care, including blood transfusions and correction of any underlying coagulopathy. Operative management should be considered early for patients with hemodynamic instability despite aggressive resuscitation.",
"     </li>",
"     <li>",
"      For persistent bleeding from a low anastomosis, a transanal operative approach is advocated:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Proctoscopy is performed to evacuate clot",
"     </li>",
"     <li>",
"      Bleeding points are suture ligated",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For persistent bleeding from higher colorectal or ileocolic anastomoses, initial endoscopic management has been advocated [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/10,12,13\">",
"       10,12,13",
"      </a>",
"      ]. However, the number of patients with anastomotic bleeding in each of these studies is small (6 to 17), thereby limiting an assessment of the true success rate. In a series of 1389 colorectal procedures, for example, 7 patients (0.5 percent) developed an anastomotic bleed: 6 were treated endoscopically to control the bleeding and 1 required operative management [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/13\">",
"       13",
"      </a>",
"      ]. A potential complication of early postoperative endoscopy is anastomotic dehiscence [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/10,15\">",
"       10,15",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Endoscopic management of bleeding includes [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/10,12\">",
"       10,12",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Isotonic saline washout",
"     </li>",
"     <li>",
"      Electrocoagulation",
"     </li>",
"     <li>",
"      Epinephrine injection",
"     </li>",
"     <li>",
"      Application of hemostatic clips",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For persistent bleeding from higher colorectal or ileocolic anastomoses, angiographic localization and control using intraarterial vasopressin has been effective in case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Theoretically, there is a risk of ischemia and anastomotic leak after intraarterial vasopressin.",
"   </p>",
"   <p>",
"    Reoperation with resection of the bleeding anastomosis is necessary when endoscopic management is not successful [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/13\">",
"     13",
"    </a>",
"    ]. There is no consensus regarding what constitutes a failure of endoscopic management in this setting. One may extrapolate from the published literature on the management of lower gastrointestinal bleeding from other causes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30841?source=see_link&amp;anchor=H5#H5\">",
"     \"Approach to resuscitation and diagnosis of acute lower gastrointestinal bleeding in the adult patient\", section on 'Colonoscopy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H800356\">",
"    <span class=\"h3\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;As indicated by the above observations, data on the management of anastomotic bleeding after colorectal surgery is limited to studies of small numbers of patients. In a literature review of 17 patients with anastomotic bleeding, nonoperative management with endoscopic electrocoagulation or blood transfusion alone was successful in 14 (82 percent of patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/10\">",
"     10",
"    </a>",
"    ]. There are no data from prospective trials addressing issues such as mortality and morbidity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H800363\">",
"    <span class=\"h2\">",
"     Dehiscence and leaks",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6666400\">",
"    <span class=\"h3\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall incidence of anastomotic dehiscence and subsequent leaks is 2 to 7 percent when performed by experienced surgeons [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/3,17-19\">",
"     3,17-19",
"    </a>",
"    ]. The lowest leak rates are found with ileocolic anastomoses (1 to 3 percent) and the highest occur with coloanal anastomosis (10 to 20 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Leaks usually become apparent between five and seven days postoperatively. Almost half of all leaks occur after the patient has been discharged, and up to 12 percent occur after postoperative day 30 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/18\">",
"     18",
"    </a>",
"    ]. Late leaks often present insidiously with low-grade fever, prolonged ileus, and nonspecific symptoms attributable to other postoperative infectious complications. Small, contained leaks present later in the clinical course and may be difficult to distinguish from postoperative abscesses by radiologic imaging, making the diagnosis uncertain and underreported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H800370\">",
"    <span class=\"h3\">",
"     Definition and manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no uniform definition of an anastomotic dehiscence and leak [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/17\">",
"     17",
"    </a>",
"    ]. In a review of 97 studies, as an example, 56 different definitions of an anastomotic leak were used [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/20\">",
"     20",
"    </a>",
"    ]. The majority of reports define an anastomotic leak using clinical signs, radiographic findings, and intraoperative findings [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical signs include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pain",
"     </li>",
"     <li>",
"      Fever",
"     </li>",
"     <li>",
"      Tachycardia",
"     </li>",
"     <li>",
"      Peritonitis",
"     </li>",
"     <li>",
"      Feculent drainage",
"     </li>",
"     <li>",
"      Purulent drainage",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The radiographic signs include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fluid collections",
"     </li>",
"     <li>",
"      Gas containing collections",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The intraoperative findings include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Gross enteric spillage",
"     </li>",
"     <li>",
"      Anastomotic disruption",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H800377\">",
"    <span class=\"h3\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for a dehiscence and leak are classified according to the site of the anastomosis (extraperitoneal or intraperitoneal). A prospective review of 1598 patients undergoing 1639 anastomotic procedures for benign or malignant colorectal disease found a significantly increased risk of anastomotic leak with extraperitoneal compared with intraperitoneal anastomoses (6.6 versus 1.5 percent; 2.4 percent overall) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H800384\">",
"    <span class=\"h4\">",
"     Extraperitoneal anastomotic leak",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major risk factors for an extraperitoneal anastomotic leak include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The distance of the anastomosis from the anal verge &mdash; Patients with a low anterior resection and an anastomosis within 5 cm from the anal verge are the highest risk group for an anastomotic leak [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/23,24\">",
"       23,24",
"      </a>",
"      ]. In the above mentioned series of 1639 procedures, the risk of a leak was highest (8 percent) with ultra-low anterior anastomoses [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Anastomotic ischemia &mdash; Two prospective studies using laser Doppler flowmetry assessed blood flow to the colon and rectum before and after mobilizing, dividing, and anastomosing the colon [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/17,25,26\">",
"       17,25,26",
"      </a>",
"      ]. A decrease in colonic tissue perfusion proximal to the anastomotic site, at the anastomotic site, and at the rectal stump was reported. The magnitude of decrease in blood flow correlated with the subsequent development of an anastomotic leak.",
"     </li>",
"     <li>",
"      Male gender &mdash; In a prospective study of 196 patients undergoing rectal cancer resections, multivariate analysis showed a significantly higher rate of anastomotic leak in men with an anastomosis less than 5 cm from the anal verge [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/21\">",
"       21",
"      </a>",
"      ]. It is likely that male gender has the greatest influence on low anastomotic leak rates because the dissection in the narrower male pelvis is more technically challenging. In contrast, male gender does not appear to be a risk factor for intraperitoneal anastomotic leaks [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Obesity &mdash; Data are conflicting regarding the role of obesity in anastomotic leak complications. A prospective review of 1417 patients found no association between obesity and the risk of an intraperitoneal anastomotic leak [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/27\">",
"       27",
"      </a>",
"      ]. However, obesity may be a risk factor for an anastomotic leak for low colorectal anastomoses. A retrospective review of 131 patients found obese patients undergoing an anterior resection less than 5 cm from the anal verge had a significantly increased risk of anastomotic leak compared with non-obese patients (33 versus 15 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H800391\">",
"    <span class=\"h4\">",
"     Intraperitoneal anastomotic leak",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major risk factors for an intraperitoneal anastomotic leak include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      American Society of Anesthesiologists (ASA) score Grade III to V &mdash; A retrospective review of 1417 patients found a significantly increased risk of leak with ASA score Grade III to V after an intraperitoneal anastomosis compared with those with an ASA score Grade I to II (4.6 versus 0.8 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Emergent surgery &mdash; The same retrospective review found a significantly increased risk of leak with emergency surgery after an intraperitoneal anastomosis compared with elective surgery (4.4 versus 1.0 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/27\">",
"       27",
"      </a>",
"      ]. For patients with both an ASA score Grade III to V and an emergency operation, the risk of an anastomotic leak was 8.1 percent.",
"     </li>",
"     <li>",
"      Prolonged operative time &mdash; A prospective study of 391 elective colorectal resections identified a significantly higher leak rate when the operative procedure was &ge;4 hours in duration compared with shorter procedures (5.1 versus 0.5 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/24\">",
"       24",
"      </a>",
"      ]. More difficult dissections and anastomoses were attributed to the longer operating times and increase in anastomotic leaks.",
"     </li>",
"     <li>",
"      Hand-sewn ileocolic anastomosis &mdash; In a meta-analysis of six trials with 955 participants with benign and malignant disease, hand-sewn anastomoses were associated with a significantly higher rate of overall anastomotic leaks compared with stapled ileocolic anastomoses (6.0 versus 1.4 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/2\">",
"       2",
"      </a>",
"      ]. For the subgroup of 825 patients with cancer, hand-sewn anastomoses were also associated with significant risk of an anastomotic leak (6.7 versus 1.3 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast to being a risk factor for extraperitoneal anastomotic leaks as noted in the preceding section, neither male gender nor obesity appears to be a risk factor for intraperitoneal anastomotic leaks [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2710307\">",
"    <span class=\"h4\">",
"     Controversial, inconclusive, or negative",
"    </span>",
"    &nbsp;&mdash;&nbsp;Controversial, inconclusive, or pertinent negative associations between the following variables and an anastomotic leak have been reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neoadjuvant radiation therapy &ndash; Retrospective studies have found a positive, inconclusive, and no association between the use of neoadjuvant radiation therapy and the risk of an anastomotic leak [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/4,17,28-31\">",
"       4,17,28-31",
"      </a>",
"      ]. There are no high quality data from randomized trials that specifically address neoadjuvant radiation therapy as a risk factor.",
"     </li>",
"     <li>",
"      Drains &ndash; It is unclear if drains are a risk factor for anastomotic leaks and the location of the anastomosis may be important. A randomized trial found no increase in anastomotic leaks with drains in patients undergoing elective colonic resection [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/32\">",
"       32",
"      </a>",
"      ], while a large observational study found a significant increase in anastomotic leaks with drains in patients undergoing a low anterior resection for rectal cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Protective stoma &ndash; The controversy regarding a protective stoma involves whether the stoma",
"      <strong>",
"       prevents",
"      </strong>",
"      a leak or reduces the clinical consequences of a leak. Proximal fecal diversion by a protective stoma (eg, loop ileostomy, loop colostomy, or end ostomy) significantly reduces the overall risk of a reoperation following an anastomotic leak.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In a prospective multicenter study of 2729 patients undergoing a low anterior resection the overall anastomotic leak rate was similar in patients with and without a stoma (14.5 versus 14.2 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/34\">",
"       34",
"      </a>",
"      ]. However, patients with a stoma had significantly lower rates of leaks that required surgical intervention (3.6 versus 10.1 percent) and a lower rate of mortality (0.9 versus 2.0 percent).",
"     </li>",
"     <li>",
"      A meta-analysis of four randomized trials including 358 patients undergoing a low anterior resection for rectal cancer found patients with a protective stoma had significantly fewer anastomotic leaks compared with patients who had no protective stoma (9.6 versus 22.8 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/35\">",
"       35",
"      </a>",
"      ]. Patients with a protective stoma had significantly fewer reoperations for leaks (odds ratio 0.27, 95% CI 0.17-0.59).",
"     </li>",
"     <li>",
"      In a randomized controlled trial of 234 patients undergoing a low anterior resection for rectal cancer that was included in the meta-analysis, the rate of anastomotic leakage with a protective stoma was significantly lower compared with no protective stoma in both men (10.0 versus 29.3 percent) and women (10.9 versus 26.7 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hand-sewn colorectal anastomosis &ndash; In contrast to ileocolic anastomoses in which hand-sewn anastomoses are associated with a significant increase in leaks [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/2\">",
"       2",
"      </a>",
"      ], the technique of performing the colorectal anastomosis, whether hand-sewn or stapled, has not been shown to affect clinical anastomotic leak rates [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/14,37\">",
"       14,37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A review of nine prospective trials of 1233 patients with a colorectal anastomosis found no significant difference in overall dehiscence and leaks for a stapled anastomosis compared with a hand-sewn anastomosis (13.0 versus 13.4 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a prospective, multicenter trial of 732 patients with a colorectal anastomosis, there was an increase in radiographically detected leaks in hand-sewn anastomoses (14.4 versus 5.2 percent), but no difference in clinically detected leak rates [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/37\">",
"       37",
"      </a>",
"      ]. No patient with a radiographic leak without clinical symptoms had an increase in morbidity. There was no difference in morbidity and mortality rates for patients with a hand-sewn or stapled anastomosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Laparoscopic procedure &ndash; Randomized trials comparing laparoscopic with open colorectal resection for cancer have failed to show any difference in the rate of anastomotic leaks [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/38,39\">",
"       38,39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Mechanical bowel preparation &ndash; The role of mechanical bowel preparation (MBP) is controversial. A meta-analysis of 13 prospective trials found no significant difference in overall anastomotic leak rate for patients with an MBP compared to those not having a MBP (4.2 versus 3.4 percent). This conclusion applied to both low anterior resection and intraperitoneal anastomosis.",
"     </li>",
"     <li>",
"      Nutrition &ndash; Nutritional factors, including hypoalbuminemia, alcohol intake, and weight loss have shown variable and conflicting results [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/40,41\">",
"       40,41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Perioperative corticosteroids &ndash; Data are inconsistent in determining the relationship between perioperative corticosteroid usage and risk of anastomotic leaks [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/3,24,42-44\">",
"       3,24,42-44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H800398\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once an anastomotic leak has been recognized, patients should receive intravenous fluid resuscitation and broad spectrum antibiotics. Further management is dictated by the clinical scenario and, if patient stability permits, radiologic investigation to localize the leak and determine its severity. Management strategies include observation, bowel rest, percutaneous drainage, colonic stenting, surgical revision, diversion, or drainage [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17361987\">",
"    <span class=\"h4\">",
"     Intraperitoneal anastomotic leak",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of an intraperitoneal anastomotic leak is dependent upon the patient&rsquo;s clinical condition, the nature of the leak, and, if an exploratory laparotomy is performed, the intraoperative findings. The following treatment options are available, depending upon the clinical stability of the patient, radiographic findings, and feasibility of image-guided percutaneous drainage:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A subclinical leak, defined as a leak detected radiographically in patients with no clinical abdominal findings, can be managed expectantly.",
"     </li>",
"     <li>",
"      For patients who present with localized peritonitis and low-grade sepsis, a diagnostic imaging work-up is initiated. We perform a CT scan with oral, intravenous, and rectal contrast. Alternatively, a water soluble contrast enema may be performed, if available in your institution. If a leak is present, the majority will be localized.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If a free intraperitoneal leak is demonstrated, the patient should be taken to the operating room for surgical management.",
"     </li>",
"     <li>",
"      If the patient is stable with small, contained abscesses (&lt;3 cm), we recommend conservative management with broad-spectrum antibiotics and bowel rest.",
"     </li>",
"     <li>",
"      For larger abscesses (&gt;3 cm), multiloculated collections, or multiple collections, an attempt at percutaneous drainage should be made. In those cases where image-guided drainage is not technically feasible or where the patient&rsquo;s clinical condition deteriorates despite drainage, surgical intervention in the form of an exploratory laparotomy should be undertaken as described in the following paragraph.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who present with generalized peritonitis or high-grade sepsis with hypotension should be resuscitated and brought to the operating room for an exploratory laparotomy on an emergent basis. Surgical management is dependent upon the intraoperative findings.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If an inoperable phlegmon is encountered, the safest approach is to place para-anastomotic drains and perform proximal temporary fecal diversion with either a loop ileostomy or colostomy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who have a major anastomotic defect (generally defined as &gt;1 cm or greater than one-third the circumference of the anastomosis) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/45\">",
"       45",
"      </a>",
"      ], the options include resection of the anastomosis with creation of an end stoma",
"      <span class=\"nowrap\">",
"       with/without",
"      </span>",
"      mucus fistula, resection of the anastomosis with re-anastomosis and proximal diversion, or, rarely, exteriorization of both ends of the stoma.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In selected patients in whom the defect is minor and the tissue quality is adequate, one may consider primary repair of the anastomosis with drain placement and proximal diversion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17362023\">",
"    <span class=\"h4\">",
"     Extraperitoneal anastomotic leak",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases, management of an extraperitoneal anastomotic leak is similar to that of an intraperitoneal leak. The following treatment options are available, depending upon the clinical stability of the patient, radiographic findings, and feasibility of image-guided percutaneous drainage:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with generalized peritonitis and high-grade sepsis, emergent operative management should be performed, as described in the previous section.",
"     </li>",
"     <li>",
"      Management of patients with a pelvic abscess depends upon the patient&rsquo;s clinical condition, location of the abscess, and whether or not the abscess is in continuity with a leak. Consideration of proximal diversion is warranted in symptomatic patients. Determination of whether the abscess is contained or is in continuity with the leak can be made by performing a water soluble contrast enema.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients with a contained abscess should be placed on intravenous antibiotics and undergo abscess drainage if the collection is larger than 3 cm. CT-guided drainage via a transabdominal, transvaginal, transanal, or transrectal route should be performed if technically feasible. Rarely, a trans-sciatic or transgluteal approach may be necessary.",
"     </li>",
"     <li>",
"      For very low pelvic abscesses that are in continuity with the anastomotic leak and which may be anatomically inaccessible by image-guided techniques, we perform an examination under anaesthesia with transrectal or trans-anastomotic drainage. This is facilitated by making a wide opening in the anastomosis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      inserting a mushroom-tipped catheter into the abscess cavity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H800405\">",
"    <span class=\"h3\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anastomotic dehiscence and leaks are associated with an increased risk of mortality compared with patients without a leak (15.8 versus 2.5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/3\">",
"     3",
"    </a>",
"    ], as well as a prolonged hospital stay, an increased rate of mortality, and an increase in cancer recurrence rates [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/27,37,46\">",
"     27,37,46",
"    </a>",
"    ]. A retrospective review of 1417 patients with an intraperitoneal anastomosis found a significantly longer length of hospital stay for patients with a leak compared with those without a leak (28 versus 10 days) as well as a significantly higher in-hospital mortality rate (32 versus 4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H588088332\">",
"    <span class=\"h4\">",
"     Local recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;An anastomotic leak is associated with an increased risk for local recurrence for rectal and colon cancer. The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of 11 prospective and retrospective studies that included 9,896 patients with rectal cancer found a significantly increased risk of local recurrence with an anastomotic leak compared with patients with no leak (OR 1.60 95% CI 1.33-1.92) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A prospective study of 1,722 patients undergoing colorectal cancer resection found a significantly higher five-year mortality rate in patients with a leak compared with those without a leak (56 versus 36 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a prospective study of 306 patients with resectable colon cancer, patients with an anastomotic leak had, at 48 months follow-up, significantly higher rates of both tumor recurrence (45 versus 30 percent) and cancer-specific mortality (53 versus 31 percent) compared with patients without an anastomotic leak [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, a meta-analysis of three prospective studies that included 1,990 patients with colon cancer only, found a nonsignificant increased risk of local recurrence with an anastomotic leak compared with patients with no leak (8.8 versus 6.6 percent, OR 2.16 95% CI 0.88&ndash;5.29) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H748238\">",
"    <span class=\"h4\">",
"     Chronic presacral sinus",
"    </span>",
"    &nbsp;&mdash;&nbsp;A chronic presacral sinus is an infrequent complication of a posterior leak in a coloanal or ileal pouch-anal anastomosis. A retrospective review of 100 consecutive cases of total mesorectal excision with proximal diverting ileostomy identified a para-anastomotic sinus in eight patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/48\">",
"     48",
"    </a>",
"    ]. Spontaneous closure occurred in three patients, and late malignant transformation developed in two. Surgical management included anastomotic excision with reanastomosis or permanent colostomy, transanal lying open of the neorectum, and fibrin glue injection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H800412\">",
"    <span class=\"h2\">",
"     Strictures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of an anastomotic stricture or stenosis after a colorectal anastomosis ranges from 0 to 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. This wide range is due at least in part to an imprecise definition of stricture. Prospective studies have defined a stricture in terms of the inability to pass a proctoscope (12 mm diameter) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/52\">",
"     52",
"    </a>",
"    ] or a larger rigid sigmoidoscope (19 mm diameter) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/51\">",
"     51",
"    </a>",
"    ] through the stenosis. A clinically significant stricture typically presents with signs of a partial or complete bowel obstruction. The incidence of symptomatic strictures ranges from 4 to 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/31,51,53\">",
"     31,51,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most patients with an anastomotic stricture do not require an intervention. This issue was addressed in a prospective study of 179 consecutive patients with a stapled colorectal anastomosis in whom a benign stenosis or inability to pass a rigid proctosigmoidoscope occurred in 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/51\">",
"     51",
"    </a>",
"    ]. Only eight patients (4 percent of all patients and 22 percent of those with a stenosis) presented with obstructive symptoms attributable to the stenosis; all eight were treated by endoscopic dilatation alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H800419\">",
"    <span class=\"h3\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;An anastomotic stricture may result from tissue ischemia, inflammation, radiation, anastomotic leak, or recurrent disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/54\">",
"     54",
"    </a>",
"    ]. The literature supporting the role of the above factors in the pathophysiology of anastomotic strictures is sparse. Both randomized trials and prospective observational studies have identified the following risk factors for stricture formation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A stapled colorectal anastomosis but not a stapled ileocolic anastomosis is associated with an increased risk of stricture formation compared with a hand-sewn anastomosis. A systematic review of seven randomized trials with 1042 patients with a colorectal anastomosis found a significantly higher rate of stricture formation with stapled anastomosis (8 versus 2 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/14\">",
"       14",
"      </a>",
"      ]. In contrast, a meta-analysis of six trials with 955 patients with an ileocolic anastomosis found no difference in the rate of stricture between the two types of anastomosis [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a prospective observational study, the risk of developing a stenosis following a colorectal anastomosis was 2.4 times greater in men compared with women (25 versus 14 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/51\">",
"       51",
"      </a>",
"      ]. This may reflect the anatomically narrow male pelvis and the associated increased technical difficulty.",
"     </li>",
"     <li>",
"      A randomized trial of 50 patients undergoing a low anterior resection found a significantly higher rate of anastomotic stricture formation in patients treated with a protective colostomy compared with no colostomy (36 versus 8 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H800426\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of an anastomotic stricture depends upon its etiology and anatomic location.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H800433\">",
"    <span class=\"h4\">",
"     Malignant strictures",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the initial resection is performed for malignancy, it is imperative to rule out local recurrence. The evaluation includes laboratory tests (CEA), radiographic imaging (CT scan, MRI, endoscopic ultrasound, or PET scan), and endoscopic biopsy of the stricture.",
"   </p>",
"   <p>",
"    Malignant recurrence is reported to be rare in early strictures (up to six months) but the risk of local malignant recurrence increases with time [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/49\">",
"     49",
"    </a>",
"    ]. In the absence of distant metastatic disease, surgical resection of a malignant anastomotic stricture should be performed, with restoration of gastrointestinal continuity if technically feasible. In the presence of distant metastatic disease or unresectable locoregional disease, proximal fecal diversion may be warranted for palliation.",
"   </p>",
"   <p>",
"    A retrospective review of 68 patients undergoing a colorectal resection for malignant disease found that tumor recurrence was responsible for seven (10 percent) anastomotic strictures [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/56\">",
"     56",
"    </a>",
"    ]. The initial management was endoscopic dilatation for all 68 patients, with a success rate of 59 percent (40 patients). For all seven patients with a stenosis secondary to recurrent tumor, the initial biopsy was negative for malignancy. Persistence or recurrence of stenosis following endoscopic dilatation led to a subsequent biopsy and the diagnosis of malignancy. Four of the seven patients were treated by a surgical resection, the other three received a palliative colostomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H800440\">",
"    <span class=\"h4\">",
"     Benign strictures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign low colorectal, coloanal, and ileoanal strictures are usually effectively treated with repeated dilatation using an examining finger or rubber dilators. Higher colorectal, colocolic, or ileocolic strictures may be managed endoscopically. Endoscopic balloon dilatation is successful in 88 to 100 percent of benign cases [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/51,56,57\">",
"     51,56,57",
"    </a>",
"    ]. Endoscopic alternatives employing the use of self-expanding metallic stents or endoscopic transanal resection of strictures are effective in treating high grade anastomotic strictures [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/58\">",
"     58",
"    </a>",
"    ]. In refractory cases, surgical revision may be required and, occasionally, permanent fecal diversion is warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H800447\">",
"    <span class=\"h3\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic dilatation is more successful and carries a lower complication rate in patients who were operated upon for benign rather than malignant disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective review of 94 patients, endoscopic dilatation was significantly more effective with a benign stricture compared with a malignant stricture (88 versus 59 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/56\">",
"       56",
"      </a>",
"      ]. The complication rate was significantly higher in patients who had previous surgery for cancer (23 versus 4 percent). Complications of endoscopic dilatation included benign restenosis (11 percent), perforation (5 percent), and abscess formation (2 percent).",
"     </li>",
"     <li>",
"      A retrospective study of 27 patients with colorectal anastomotic strictures refractory to endoscopic management underwent surgical revision with either a colorectal or coloanal anastomosis without a mortality and no evidence of restenosis in any patient at a median follow-up of 28 months [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/49\">",
"       49",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H800454\">",
"    <span class=\"h2\">",
"     Fistulas",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of a fistula occurring after a colorectal, coloanal, or an ileocolic anastomosis ranges between 1 to 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/29,59-64\">",
"     29,59-64",
"    </a>",
"    ]. Rectourinary (rectovesical, rectourethral) fistulas following colorectal surgery are rare [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. Data are limited on the frequency with which rectourinary fistulas are malignant. In the largest series of patients with an acquired rectourinary fistula, only 3 of 15 fistulas were related to rectal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fistulas can develop between the anastomosis and the skin, vagina, genitourinary system, and presacral space. Enterocutaneous (colocutaneous) fistulas that develop between the colorectal anastomosis and the skin are usually a late manifestation of an unrecognized anastomotic leak. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32951?source=see_link\">",
"     \"Rectovaginal, anovaginal, and colovesical fistulas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/0/6152?source=see_link\">",
"     \"Principles of management of enteric fistulas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18824438\">",
"    <span class=\"h3\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for the development of a fistula include an anastomotic dehiscence and leak, an anastomosis &le;5 cm from the anal verge, preoperative radiation therapy, advanced cancer, resection for cancer, abscess, double stapled anastomosis, and inadvertent inclusion of the vaginal wall in a stapled anastomosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/29,60,61,67,68\">",
"     29,60,61,67,68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following findings have been noted in different studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective review of three cohorts totalling 390 women undergoing a low anterior resection for rectal cancer, 20 (5.1 percent) developed a symptomatic anastomotic vaginal fistula (AVF) and 32 (8.2 percent) developed a conventional anastomotic leak [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/29\">",
"       29",
"      </a>",
"      ]. The AVF was diagnosed clinically as an evident communication between the vagina and the anastomosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Compared with women who did not develop an AVF or conventional anastomotic leak, women with an AVF were significantly more likely to have an anastomosis &le;5 cm from the anal verge (65 versus 19 percent), received preoperative radiation therapy (85 versus 38 percent), and have Union for International Cancer Control (UICC) cancer stage IV (30 versus 8 percent).",
"     </li>",
"     <li>",
"      Compared with women who did develop a conventional anastomotic leak, women with an AVF were significantly more likely to have an anastomosis &le;5 cm from the anal verge (4.3 versus 5.0 percent), a lower body mass index (22 versus 25",
"      <span class=\"nowrap\">",
"       kg/m2),",
"      </span>",
"      and a diagnosis after hospital discharge (70 versus 41 percent). An AVF presented later than a conventional leak (25 versus 11 days).",
"     </li>",
"     <li>",
"      Intraoperative vaginal perforation, salpingo-oophorectomy, concomitant hysterectomy, and a previous hysterectomy were not associated with the formation of an AVF or a conventional leak.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A questionnaire sent to members of the American Society of Colon and Rectal Surgeons regarding the incidence and treatment of rectovaginal fistulas (RVF) following a low anterior resection (LAR) or an abdominal perineal resection (APR) reported on results of approximately 6300 LAR and 2100 APR procedures [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/60\">",
"       60",
"      </a>",
"      ]. Fifty-seven patients developed an RVF. The hypothesized causes of the RVF included inadvertently including the vaginal wall with a stapled anastomosis, spontaneous drainage of a pelvic abscess, or recurrent tumor. Fifty-four fistulas were clinically evident, 53 occurred in a stapled anastomosis, and 48 were directly adjacent to the anastomotic site on clinical examination.",
"     </li>",
"     <li>",
"      In a retrospective review of 161 patients undergoing a low anterior resection (LAR) for a primary rectal cancer, 16 (10 percent) developed a rectovaginal fistula (RVF) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/61\">",
"       61",
"      </a>",
"      ]. The risk of a RVF was greatest for patients treated with an intersphincteric resection (49 percent), a very low LAR (18 percent), LAR (7 percent), and those with a double stapled anastomosis compared with a single stapled anastomosis (15 versus 5 percent). No patient treated with a high anterior resection procedure developed a RVF.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H800468\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fistulas are best managed by addressing the sites that are involved. Options include conservative management, diverting colostomy, or endoanal or endovaginal advancement flap reconstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/61\">",
"     61",
"    </a>",
"    ]. There are no high quality data available from prospective trials.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Rectovaginal and colovaginal fistulas",
"      </strong>",
"      &mdash; Spontaneous closure is unlikely for patients with colovaginal or rectovaginal fistulas, and proximal fecal diversion may be necessary to alleviate symptoms. The optimal time for surgical excision and repair of the fistula is controversial. High anastomotic vaginal fistulas may require a colorectal resection while low fistulas may be amenable to transvaginal or transanal excision and repair [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/62\">",
"       62",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32951?source=see_link&amp;anchor=H10#H10\">",
"       \"Rectovaginal, anovaginal, and colovesical fistulas\", section on 'Surgical principles'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Colocutaneous fistulas",
"      </strong>",
"      &mdash; Conservative and supportive management is the initial approach for patients with a colocutaneous fistula, since approximately one-half will close spontaneously at a mean of 30 days (range 10 to 180 days) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/69\">",
"       69",
"      </a>",
"      ]. If the fistula persists longer than six weeks or is a high output fistula, it is less likely to close spontaneously. Definitive operative intervention should be delayed for approximately three to six months to allow for resolution of sepsis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      to restore nutritional status. The management of enteric fistulas, including local control and nutritional support, is discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/0/6152?source=see_link\">",
"       \"Principles of management of enteric fistulas\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Rectourinary fistulas",
"      </strong>",
"      &mdash; Data are limited on the management of rectourinary fistulas. In a series of five patients with a rectourinary fistula related to a rectal cancer, surgical management included excision and repair or reconstruction in three, a permanent colostomy and a permanent urinary diversion in one, and a permanent colostomy with temporary urinary diversion in one [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/66\">",
"       66",
"      </a>",
"      ]. All patients experienced relief of symptoms. The optimal surgical management of a rectourinary fistula for patients with locally curative disease is an excision and with reconstructive procedures. For patients with advanced or unresectable disease, a permanent fecal",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      urinary diversion procedure is necessary.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H800475\">",
"    <span class=\"h3\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Morbidity and mortality with fistulas varies with the location of the fistula.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rectovaginal fistulas &ndash; Outcomes related to the management of rectovaginal fistulas following colorectal surgery are difficult to quantitate because of the small number of reported cases. The following findings are illustrative:",
"     </li>",
"     <li>",
"      A retrospective review included 16 patients with rectovaginal fistulas following low anterior resection for rectal cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/61\">",
"       61",
"      </a>",
"      ]. Spontaneous closure of the fistula occurred in six patients, reconstructive surgery by various methods resulted in complete healing in eight patients, and death due to metastatic disease occurred in two patients.",
"     </li>",
"     <li>",
"      In a series of nine patients with rectovaginal fistulas following colorectal surgery, four required permanent fecal diversion to manage their fistula [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Colocutaneous fistulas &ndash; Colocutaneous fistulas are generally low output fistulas and have an almost 50 percent chance of spontaneously closing. In contrast, high output fistulas are associated with mortality rates between 5 to 20 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/69,70\">",
"       69,70",
"      </a>",
"      ] and fistulas that do not spontaneously close are associated with a high morbidity rate [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/70\">",
"       70",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A retrospective review of 61 patients referred to a specialized center reported the complication and mortality rates following surgical repair of an enterocutaneous fistula with an open abdominal wound [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/70\">",
"       70",
"      </a>",
"      ]. Initial management included treatment of sepsis and restoration of nutritional status, which was then followed by an operative resection of the fistula and closure of the abdominal wound. There were three postoperative deaths, seven recurrent fistulas, and 52 patients with postoperative respiratory and surgical site infections. Recurrent fistulas occurred only in the patients with reconstruction of the abdominal wall with prosthetic mesh compared with suture closure (7 of 29 versus 0 of 34 patients).",
"     </li>",
"     <li>",
"      Rectourinary fistulas &ndash; There are few reported cases of a rectourinary fistula [",
"      <a class=\"abstract\" href=\"UTD.htm?4/5/4186/abstract/66\">",
"       66",
"      </a>",
"      ] and no high quality data from prospective trials or large retrospective reviews reporting outcomes following a colorectal resection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17362063\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The safety of colorectal surgery, as performed in patients with colorectal cancer and inflammatory bowel disease, has improved dramatically over the years due to improvements in preoperative preparation, antibiotic prophylaxis, surgical technique, and postoperative management. Anastomotic complications following colorectal surgery include bleeding, dehiscence and leakage, strictures, and fistulas.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For management of major anastomotic bleeding, the initial management should be conservative with supportive care, including blood transfusions and correction of any underlying coagulopathy. Endoscopic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      surgical intervention should be reserved for unstable patients or those with persistent bleeding, despite conservative measures. (See",
"      <a class=\"local\" href=\"#H800342\">",
"       'Major bleeding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of an extraperitoneal dehiscence includes percutaneous drainage for a low pelvic abscess that is in continuity with anastomotic leak. For patients with a low pelvic abscess in continuity with the anastomotic leak that are not amenable to percutaneous drainage, an examination under anaesthesia with transrectal or trans-anastomotic drainage should be performed. Consideration of proximal fecal diversion is warranted in symptomatic patients. (See",
"      <a class=\"local\" href=\"#H800384\">",
"       'Extraperitoneal anastomotic leak'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Options for management of an intraperitoneal dehiscence include conservative management with broad spectrum antibiotics and bowel rest, image-guided percutaneous drainage of abscesses, temporary fecal diversion",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      drainage, or resection of the anastomosis. Early operative intervention is warranted for patients with generalized peritonitis and high-grade sepsis or patients with a free intraperitoneal leak on radiographic imaging. (See",
"      <a class=\"local\" href=\"#H800391\">",
"       'Intraperitoneal anastomotic leak'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial management for anastomotic strictures includes finger dilatation for low anastomoses and endoscopic balloon dilatation for higher anastomosis. It is imperative to rule out local recurrence if the initial resection was performed for malignancy. In refractory cases, surgical revision may be required and, occasionally, permanent fecal diversion is warranted. (See",
"      <a class=\"local\" href=\"#H800412\">",
"       'Strictures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Colocutaneous fistulas can be managed conservatively as most will close without operative intervention. (See",
"      <a class=\"local\" href=\"#H800454\">",
"       'Fistulas'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anastomotic vaginal fistulas should be managed initially by proximal fecal diversion then definitive surgical repair for symptomatic women. (See",
"      <a class=\"local\" href=\"#H800454\">",
"       'Fistulas'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/1\">",
"      Paun BC, Cassie S, MacLean AR, et al. Postoperative complications following surgery for rectal cancer. Ann Surg 2010; 251:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/2\">",
"      Choy PY, Bissett IP, Docherty JG, et al. Stapled versus handsewn methods for ileocolic anastomoses. Cochrane Database Syst Rev 2007; :CD004320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/3\">",
"      Slieker JC, Komen N, Komen NA, et al. Long-term and perioperative corticosteroids in anastomotic leakage: a prospective study of 259 left-sided colorectal anastomoses. Arch Surg 2012; 147:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/4\">",
"      Alves A, Panis Y, Mathieu P, et al. Postoperative mortality and morbidity in French patients undergoing colorectal surgery: results of a prospective multicenter study. Arch Surg 2005; 140:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/5\">",
"      Fazio VW, Tekkis PP, Remzi F, Lavery IC. Assessment of operative risk in colorectal cancer surgery: the Cleveland Clinic Foundation colorectal cancer model. Dis Colon Rectum 2004; 47:2015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/6\">",
"      Prystowsky JB, Bordage G, Feinglass JM. Patient outcomes for segmental colon resection according to surgeon's training, certification, and experience. Surgery 2002; 132:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/7\">",
"      Ragg JL, Watters DA, Guest GD. Preoperative risk stratification for mortality and major morbidity in major colorectal surgery. Dis Colon Rectum 2009; 52:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/8\">",
"      Tekkis PP, Poloniecki JD, Thompson MR, Stamatakis JD. Operative mortality in colorectal cancer: prospective national study. BMJ 2003; 327:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/9\">",
"      Leung E, Ferjani AM, Stellard N, Wong LS. Predicting post-operative mortality in patients undergoing colorectal surgery using P-POSSUM and CR-POSSUM scores: a prospective study. Int J Colorectal Dis 2009; 24:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/10\">",
"      Cirocco WC, Golub RW. Endoscopic treatment of postoperative hemorrhage from a stapled colorectal anastomosis. Am Surg 1995; 61:460.",
"     </a>",
"    </li>",
"    <li>",
"     Dietz, DW, Bailey, HR. Postoperative complications. In: ASCRS Textbook of Colon and Rectal Surgery, Church, JM, Beck, DE, Wolff, BG,  Fleshman, JW, Pemberton, JH, (Eds), Springer-Verlag New York, LLC, New York 2006. p.141.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/12\">",
"      Malik AH, East JE, Buchanan GN, Kennedy RH. Endoscopic haemostasis of staple-line haemorrhage following colorectal resection. Colorectal Dis 2008; 10:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/13\">",
"      Mart&iacute;nez-Serrano MA, Par&eacute;s D, Pera M, et al. Management of lower gastrointestinal bleeding after colorectal resection and stapled anastomosis. Tech Coloproctol 2009; 13:49.",
"     </a>",
"    </li>",
"    <li>",
"     Matos D, Atallah &Aacute;N, Castro AA, Silva Lustosa SA. Stapled versus handsewn methods for colorectal anastomosis surgery. Cochrane Database Syst Rev 2008; :CD003144.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/15\">",
"      Aurello P, D'Angelo F, Pozzi G, et al. [Therapy of massive anastomotic hemorrhage after anterior mechanical rectocolonic resection]. G Chir 1991; 12:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/16\">",
"      Atabek U, Pello MJ, Spence RK, et al. Arterial vasopressin for control of bleeding from a stapled intestinal anastomosis. Report of two cases. Dis Colon Rectum 1992; 35:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/17\">",
"      Kingham TP, Pachter HL. Colonic anastomotic leak: risk factors, diagnosis, and treatment. J Am Coll Surg 2009; 208:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/18\">",
"      Hyman N, Manchester TL, Osler T, et al. Anastomotic leaks after intestinal anastomosis: it's later than you think. Ann Surg 2007; 245:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/19\">",
"      Park JS, Choi GS, Kim SH, et al. Multicenter Analysis of Risk Factors for Anastomotic Leakage After Laparoscopic Rectal Cancer Excision: The Korean Laparoscopic Colorectal Surgery Study Group. Ann Surg 2013; 257:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/20\">",
"      Bruce J, Krukowski ZH, Al-Khairy G, et al. Systematic review of the definition and measurement of anastomotic leak after gastrointestinal surgery. Br J Surg 2001; 88:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/21\">",
"      Law WI, Chu KW, Ho JW, Chan CW. Risk factors for anastomotic leakage after low anterior resection with total mesorectal excision. Am J Surg 2000; 179:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/22\">",
"      Lipska MA, Bissett IP, Parry BR, Merrie AE. Anastomotic leakage after lower gastrointestinal anastomosis: men are at a higher risk. ANZ J Surg 2006; 76:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/23\">",
"      Platell C, Barwood N, Dorfmann G, Makin G. The incidence of anastomotic leaks in patients undergoing colorectal surgery. Colorectal Dis 2007; 9:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/24\">",
"      Konishi T, Watanabe T, Kishimoto J, Nagawa H. Risk factors for anastomotic leakage after surgery for colorectal cancer: results of prospective surveillance. J Am Coll Surg 2006; 202:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/25\">",
"      Boyle NH, Manifold D, Jordan MH, Mason RC. Intraoperative assessment of colonic perfusion using scanning laser Doppler flowmetry during colonic resection. J Am Coll Surg 2000; 191:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/26\">",
"      Vignali A, Gianotti L, Braga M, et al. Altered microperfusion at the rectal stump is predictive for rectal anastomotic leak. Dis Colon Rectum 2000; 43:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/27\">",
"      Choi HK, Law WL, Ho JW. Leakage after resection and intraperitoneal anastomosis for colorectal malignancy: analysis of risk factors. Dis Colon Rectum 2006; 49:1719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/28\">",
"      Rullier E, Laurent C, Garrelon JL, et al. Risk factors for anastomotic leakage after resection of rectal cancer. Br J Surg 1998; 85:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/29\">",
"      Matthiessen P, Hansson L, Sj&ouml;dahl R, Ruteg&aring;rd J. Anastomotic-vaginal fistula (AVF) after anterior resection of the rectum for cancer--occurrence and risk factors. Colorectal Dis 2010; 12:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/30\">",
"      Chambers WM, Mortensen NJ. Postoperative leakage and abscess formation after colorectal surgery. Best Pract Res Clin Gastroenterol 2004; 18:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/31\">",
"      Vignali A, Fazio VW, Lavery IC, et al. Factors associated with the occurrence of leaks in stapled rectal anastomoses: a review of 1,014 patients. J Am Coll Surg 1997; 185:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/32\">",
"      Merad F, Yahchouchi E, Hay JM, et al. Prophylactic abdominal drainage after elective colonic resection and suprapromontory anastomosis: a multicenter study controlled by randomization. French Associations for Surgical Research. Arch Surg 1998; 133:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/33\">",
"      Yeh CY, Changchien CR, Wang JY, et al. Pelvic drainage and other risk factors for leakage after elective anterior resection in rectal cancer patients: a prospective study of 978 patients. Ann Surg 2005; 241:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/34\">",
"      Gastinger I, Marusch F, Steinert R, et al. Protective defunctioning stoma in low anterior resection for rectal carcinoma. Br J Surg 2005; 92:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/35\">",
"      H&uuml;ser N, Michalski CW, Erkan M, et al. Systematic review and meta-analysis of the role of defunctioning stoma in low rectal cancer surgery. Ann Surg 2008; 248:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/36\">",
"      Matthiessen P, Hallb&ouml;&ouml;k O, Ruteg&aring;rd J, et al. Defunctioning stoma reduces symptomatic anastomotic leakage after low anterior resection of the rectum for cancer: a randomized multicenter trial. Ann Surg 2007; 246:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/37\">",
"      Docherty JG, McGregor JR, Akyol AM, et al. Comparison of manually constructed and stapled anastomoses in colorectal surgery. West of Scotland and Highland Anastomosis Study Group. Ann Surg 1995; 221:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/38\">",
"      Clinical Outcomes of Surgical Therapy Study Group. A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med 2004; 350:2050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/39\">",
"      Guillou PJ, Quirke P, Thorpe H, et al. Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial. Lancet 2005; 365:1718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/40\">",
"      Iancu C, Mocan LC, Todea-Iancu D, et al. Host-related predictive factors for anastomotic leakage following large bowel resections for colorectal cancer. J Gastrointestin Liver Dis 2008; 17:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/41\">",
"      M&auml;kel&auml; JT, Kiviniemi H, Laitinen S. Risk factors for anastomotic leakage after left-sided colorectal resection with rectal anastomosis. Dis Colon Rectum 2003; 46:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/42\">",
"      Post S, Betzler M, von Ditfurth B, et al. Risks of intestinal anastomoses in Crohn's disease. Ann Surg 1991; 213:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/43\">",
"      Tr&eacute;sallet C, Royer B, Godiris-Petit G, Menegaux F. Effect of systemic corticosteroids on elective left-sided colorectal resection with colorectal anastomosis. Am J Surg 2008; 195:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/44\">",
"      Gorissen KJ, Benning D, Berghmans T, et al. Risk of anastomotic leakage with non-steroidal anti-inflammatory drugs in colorectal surgery. Br J Surg 2012; 99:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/45\">",
"      Phitayakorn R, Delaney CP, Reynolds HL, et al. Standardized algorithms for management of anastomotic leaks and related abdominal and pelvic abscesses after colorectal surgery. World J Surg 2008; 32:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/46\">",
"      Walker KG, Bell SW, Rickard MJ, et al. Anastomotic leakage is predictive of diminished survival after potentially curative resection for colorectal cancer. Ann Surg 2004; 240:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/47\">",
"      Mirnezami A, Mirnezami R, Chandrakumaran K, et al. Increased local recurrence and reduced survival from colorectal cancer following anastomotic leak: systematic review and meta-analysis. Ann Surg 2011; 253:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/48\">",
"      Arumainayagam N, Chadwick M, Roe A. The fate of anastomotic sinuses after total mesorectal excision for rectal cancer. Colorectal Dis 2009; 11:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/49\">",
"      Schlegel RD, Dehni N, Parc R, et al. Results of reoperations in colorectal anastomotic strictures. Dis Colon Rectum 2001; 44:1464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/50\">",
"      Shimada S, Matsuda M, Uno K, et al. A new device for the treatment of coloproctostomic stricture after double stapling anastomoses. Ann Surg 1996; 224:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/51\">",
"      Bannura GC, Cumsille MA, Barrera AE, et al. Predictive factors of stenosis after stapled colorectal anastomosis: prospective analysis of 179 consecutive patients. World J Surg 2004; 28:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/52\">",
"      Luchtefeld MA, Milsom JW, Senagore A, et al. Colorectal anastomotic stenosis. Results of a survey of the ASCRS membership. Dis Colon Rectum 1989; 32:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/53\">",
"      Fingerhut A, Elhadad A, Hay JM, et al. Infraperitoneal colorectal anastomosis: hand-sewn versus circular staples. A controlled clinical trial. French Associations for Surgical Research. Surgery 1994; 116:484.",
"     </a>",
"    </li>",
"    <li>",
"     Corman, ML. Carcinoma of the Rectum. In: Colon and Rectal Surgery 5th edition, Corman, ML (Ed), Lippincott, Williams, and Wilkins, Philadelphia 2005. p. 1002",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/55\">",
"      Graffner H, Fredlund P, Olsson SA, et al. Protective colostomy in low anterior resection of the rectum using the EEA stapling instrument. A randomized study. Dis Colon Rectum 1983; 26:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/56\">",
"      Suchan KL, Muldner A, Manegold BC. Endoscopic treatment of postoperative colorectal anastomotic strictures. Surg Endosc 2003; 17:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/57\">",
"      Ambrosetti P, Francis K, De Peyer R, Frossard JL. Colorectal anastomotic stenosis after elective laparoscopic sigmoidectomy for diverticular disease: a prospective evaluation of 68 patients. Dis Colon Rectum 2008; 51:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/58\">",
"      Forshaw MJ, Maphosa G, Sankararajah D, et al. Endoscopic alternatives in managing anastomotic strictures of the colon and rectum. Tech Coloproctol 2006; 10:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/59\">",
"      Goriainov V, Miles AJ. Anastomotic leak rate and outcome for laparoscopic intra-corporeal stapled anastomosis. J Minim Access Surg 2010; 6:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/60\">",
"      Rex JC Jr, Khubchandani IT. Rectovaginal fistula: complication of low anterior resection. Dis Colon Rectum 1992; 35:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/61\">",
"      Kosugi C, Saito N, Kimata Y, et al. Rectovaginal fistulas after rectal cancer surgery: Incidence and operative repair by gluteal-fold flap repair. Surgery 2005; 137:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/62\">",
"      Fleshner PR, Schoetz DJ Jr, Roberts PL, et al. Anastomotic-vaginal fistula after colorectal surgery. Dis Colon Rectum 1992; 35:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/63\">",
"      Fazio VW, Zutshi M, Remzi FH, et al. A randomized multicenter trial to compare long-term functional outcome, quality of life, and complications of surgical procedures for low rectal cancers. Ann Surg 2007; 246:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/64\">",
"      Remzi FH, El Gazzaz G, Kiran RP, et al. Outcomes following Turnbull-Cutait abdominoperineal pull-through compared with coloanal anastomosis. Br J Surg 2009; 96:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/65\">",
"      Mu&ntilde;oz M, Nelson H, Harrington J, et al. Management of acquired rectourinary fistulas: outcome according to cause. Dis Colon Rectum 1998; 41:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/66\">",
"      Nunoo-Mensah JW, Kaiser AM, Wasserberg N, et al. Management of acquired rectourinary fistulas: how often and when is permanent fecal or urinary diversion necessary? Dis Colon Rectum 2008; 51:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/67\">",
"      Sugarbaker PH. Rectovaginal fistula following low circular stapled anastomosis in women with rectal cancer. J Surg Oncol 1996; 61:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/68\">",
"      Arbman G. Rectovaginal fistulas and the double-stapling technique. Dis Colon Rectum 1993; 36:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/69\">",
"      Martinez JL, Luque-de-Leon E, Mier J, et al. Systematic management of postoperative enterocutaneous fistulas: factors related to outcomes. World J Surg 2008; 32:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/5/4186/abstract/70\">",
"      Connolly PT, Teubner A, Lees NP, et al. Outcome of reconstructive surgery for intestinal fistula in the open abdomen. Ann Surg 2008; 247:440.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15687 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-EC2EE36D8B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_5_4186=[""].join("\n");
var outline_f4_5_4186=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17362063\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H800314\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H800321\">",
"      MORBIDITY AND MORTALITY RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H800328\">",
"      ANASTOMOTIC COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18827910\">",
"      Minor bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H800342\">",
"      Major bleeding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H800349\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H800356\">",
"      - Outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H800363\">",
"      Dehiscence and leaks",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6666400\">",
"      - Incidence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H800370\">",
"      - Definition and manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H800377\">",
"      - Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H800384\">",
"      Extraperitoneal anastomotic leak",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H800391\">",
"      Intraperitoneal anastomotic leak",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2710307\">",
"      Controversial, inconclusive, or negative",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H800398\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H17361987\">",
"      Intraperitoneal anastomotic leak",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H17362023\">",
"      Extraperitoneal anastomotic leak",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H800405\">",
"      - Outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H588088332\">",
"      Local recurrence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H748238\">",
"      Chronic presacral sinus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H800412\">",
"      Strictures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H800419\">",
"      - Risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H800426\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H800433\">",
"      Malignant strictures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H800440\">",
"      Benign strictures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H800447\">",
"      - Outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H800454\">",
"      Fistulas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18824438\">",
"      - Risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H800468\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H800475\">",
"      - Outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17362063\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30841?source=related_link\">",
"      Approach to resuscitation and diagnosis of acute lower gastrointestinal bleeding in the adult patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29513?source=related_link\">",
"      Diagnostic approach to lower gastrointestinal bleeding in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/57/1946?source=related_link\">",
"      Management of intra-abdominal, pelvic, and genitourinary complications of colorectal surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38137?source=related_link\">",
"      Overview of surgical procedures for resectable primary rectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/49/30489?source=related_link\">",
"      Overview of the management of primary colon cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/0/6152?source=related_link\">",
"      Principles of management of enteric fistulas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32951?source=related_link\">",
"      Rectovaginal, anovaginal, and colovesical fistulas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4906?source=related_link\">",
"      Surgical management of ulcerative colitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_5_4187="Other conditions of AC joint";
var content_f4_5_4187=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F66318&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F66318&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Other conditions of the acromioclavicular joint",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Synovial cyst or ganglion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Septic arthritis (eg, staph, TB)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Crystal arthropathy (gout, pseudogout)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inflammatory arthritis (rheumatoid arthritis, Crohns enteropathic arthritis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Synovial disorders (chondromatosis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Distal clavicular and acromial tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Os acromiale syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intra-articular fractures of the distal clavicle or acromion",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_5_4187=[""].join("\n");
var outline_f4_5_4187=null;
var title_f4_5_4188="Normal values impedance pH";
var content_f4_5_4188=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F56522&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F56522&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Normal values for combined impedance-pH monitoring based on 95th percentile data in healthy volunteers off and on acid suppressive therapy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        <p>",
"         Off therapy",
"        </p>",
"        <p>",
"         (N = 60)",
"        </p>",
"       </td>",
"       <td class=\"subtitle1\">",
"        <p>",
"         On therapy (PPI twice daily)",
"        </p>",
"        <p>",
"         (N = 20)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Esophageal pH data",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        Percent time pH &lt;4",
"       </td>",
"       <td>",
"        Total",
"       </td>",
"       <td>",
"        6.7 percent",
"       </td>",
"       <td>",
"        1.3 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Upright",
"       </td>",
"       <td>",
"        9.7 percent",
"       </td>",
"       <td>",
"        2.2 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recumbent",
"       </td>",
"       <td>",
"        2.1 percent",
"       </td>",
"       <td>",
"        0.0 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Esophageal MII-data",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        Nr. reflux episodes",
"       </td>",
"       <td>",
"        Total",
"       </td>",
"       <td>",
"        73",
"       </td>",
"       <td>",
"        48",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acid",
"       </td>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Non-acid",
"       </td>",
"       <td>",
"        27",
"       </td>",
"       <td>",
"        44",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      1. Shay, S, Tutuian, R, Sifrim, D, et al. Twenty-Four Hour Ambulatory Simultaneous Impedance and pH Monitoring: A Multicenter Report of Normal Values From 60 Healthy Volunteers. Am J Gastroenterol 2004; 99:1037.",
"      <br>",
"       2. Tutuian, R, Mainie, I, Agrawal, A, et al. Normal values for ambulatory 24-h combined impedance-pH monitoring on acid suppressive therapy. Gastroenterology 2006; 130 Suppl 2:A171.",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_5_4188=[""].join("\n");
var outline_f4_5_4188=null;
var title_f4_5_4189="AUA Urinary Symptom Score";
var content_f4_5_4189=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F81331&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F81331&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    American Urological Association Urinary symptom score (International Prostate Symptom Score [IPSS])",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Questions to be answered",
"       </td>",
"       <td class=\"subtitle1\">",
"        Not at all",
"       </td>",
"       <td class=\"subtitle1\">",
"        Less than 1 time in 5",
"       </td>",
"       <td class=\"subtitle1\">",
"        Less than half the time",
"       </td>",
"       <td class=\"subtitle1\">",
"        About half the time",
"       </td>",
"       <td class=\"subtitle1\">",
"        More than half the time",
"       </td>",
"       <td class=\"subtitle1\">",
"        Almost always",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"6\" rowspan=\"1\">",
"        (Circle one number on each line)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Over the past month, how often have you had a sensation of not emptying your bladder completely after you finished urinating?",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Over the past month, how often have you had to urinate again less than 2 hours after you finished urinating?",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Over the past month, how often have you found you stopped and started again several times when you urinated?",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Over the past month, how often have you found it difficult to postpone urination?",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Over the past month, how often have you had a weak urinary stream?",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6. Over the past month, how often have you had to push or strain to begin urination?",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7. Over the past month, how many times did you most typically",
"get up to urinate from the time you went to bed at night until the time",
"you got up in the morning?",
"       </td>",
"       <td>",
"        0 (none)",
"       </td>",
"       <td>",
"        1 (1 time)",
"       </td>",
"       <td>",
"        2 (2 times)",
"       </td>",
"       <td>",
"        3 (3 times)",
"       </td>",
"       <td>",
"        4 (4 times)",
"       </td>",
"       <td>",
"        5 (5 or more times)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\" rowspan=\"1\">",
"        Sum of circled numbers (AUA symptom score): _______&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"7\" rowspan=\"1\">",
"        0 to 7: Mild symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"7\" rowspan=\"1\">",
"        8 to 19: Moderate symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"7\" rowspan=\"1\">",
"        20 to 35: Severe symptoms",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Barry, MJ, Fowler, FJ Jr, O'Leary, MP, et al. The American Urological Association Symptom Index for Benign Prostatic Hyperplasia. J Urol 1992; 148:1549. Copyright &copy; 1992 Lippincott Williams and Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_5_4189=[""].join("\n");
var outline_f4_5_4189=null;
var title_f4_5_4190="Glutathione synthesis pathway";
var content_f4_5_4190=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F75361&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F75361&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Biosynthesis of glutathione",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 397px; height: 347px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure illustrates the pathway for biosynthesis of glutathione from cysteine, glutamic acid, ATP, and glycine. The end product of these reactions, glutathione, serves as a feedback inhibitor of the first enzyme in the pathway, gamma-glutamyl cysteine synthetase. In the absence of glutathione synthetase, this inhibition cannot take place, and increased amounts of the intermediate, gamma-glutamyl cysteine are formed. This is converted to the intermediate 5' oxyproline, which is present in increased amounts in glutathione synthetase deficiency.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_5_4190=[""].join("\n");
var outline_f4_5_4190=null;
var title_f4_5_4191="Morquio syndrome radiograph of C-spine";
var content_f4_5_4191=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F79215&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F79215&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Spine radiograph in a patient with mucopolysaccharidosis IV (MPS IV, Morquio syndrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 308px; height: 332px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Radiograph of the cervical spine in mucopolysaccharidosis IV (MPS IV, Morquio syndrome). The odontoid is severely hypoplastic (large arrow), and there is anterior displacement of C1 on C2 (small arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ed Wraith, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_5_4191=[""].join("\n");
var outline_f4_5_4191=null;
